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The receptor tyrosine kinase HER3 is well established as a compelling therapeutic 
target in numerous cancers, including ovarian cancer. HER3 potently activates the 
PI3K/Akt pro-survival pathway, mediates drug resistance, and is implicated in cancer 
progression and poor clinical outcomes. Yet, conventional small molecule- and 
monoclonal antibody-based approaches have so far failed to yield a widely used 
therapeutic that directly targets HER3. Here, we investigated a novel approach 
involving specific, multivalent engagement of HER3 with affibody molecules as an 
alternative to existing therapeutics. We established that multivalent HER3-targeted 
affibodies more effectively inhibit neuregulin 1β-mediated HER3 activation 
compared to monovalent affibodies; these multivalent ligands induced rapid and 
prolonged HER3 downregulation, indicating a potentially valuable mechanism of 
action to limit HER3-mediated pro-mitogenic signaling and acquired resistance. 
  
HER3-targeted affibodies also proved highly amenable to molecular engineering 
approaches, as modulation of linker length, valency, and albumin binding domain 
(ABD) fusion placement allowed for robust retention of ligand bioactivity. We further 
report significant mechanistic evidence supporting HER3 downregulation as a highly 
specific phenomenon prompted by HER3 sequestration by multivalent ligands. Most 
importantly, we show that both monovalent and bivalent HER3-targeted affibody-
ABD fusion proteins significantly reduce tumor burden in an adriamycin-resistant 
ovarian cancer model in mice. Overall, these data serve as compelling evidence for 
HER3 multivalent ligands as promising experimental therapeutics for the treatment of 
ovarian cancer as single agents as well as in combination with other drugs. Further, 
HER3 affibodies represent a promising template for development of targeted 
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Chapter 1: Introduction  
1.1 Cancer: a general overview 
 
Cancer, defined as the uncontrolled growth of abnormal cells, is the 2nd leading cause 
of death in the United States, accounting for 1 in 4 deaths [1]. Over 1.6 million 
Americans are expected to be diagnosed with cancer in 2016, which will account for 
600,000 deaths this year and over 1,600 deaths per day in the United States [1]. 
Notwithstanding these statistics, the 5 year survival rates for patient’s diagnosed with 
certain cancers continue to increase as improved and more informed treatment 
options are developed [2].  
 
Cancer can be caused by external factors such as diet, smoking and exposure to 
carcinogenic material as well as from internal factors such as inherited genetic 
mutations [1]. Treatment decisions are largely dictated by the tissue involved, the 
stage of progression, the cancer’s biological features and whether or not the cancer 
has recurred [3]. Common treatment options include surgery, chemotherapy, radiation 
therapy, hormone therapy, immune therapy, and targeted therapy [4,5].  
 
Cancer stage is a predictor of clinical outcome [3] and can most generally be 
classified as in situ, local, regional or distal with respect to increased invasion [3].  
More specifically, clinicians use the TNM staging system, which designates primary 
tumor (T), lymph node involvement (N), and distant metastases (M) [3]. The most 




combined with adjuvant radiation or chemotherapy in an effort to combat cancer cells 
that were potentially missed during the surgical resection [3]. For more advanced 
stage tumors, chemotherapy and radiation therapy are also common, however these 
therapies have limited efficacy, and cause side effects that limit treatment regimens 
[5]. Early detection is crucial for survival chances; for example, breast cancer patients 
with local stage tumors have a 5-year survival of nearly 99%, which drops to 85% for 
patients with regional tumors, and plummets to 25% for those with distant tumors [3].   
 
Based on these statistics, more effective treatment for distant and refractory tumors is 
a clear unmet clinical need. One clinically available solution is the systemic delivery 
of targeted therapeutics that bind to and inhibit biological features that are unique or 
overexpressed on cancer cells. Targeted therapies allow for improved selectivity for 
cancer cells and reduced side effects compared to chemotherapeutic agents [5].       
 
Clinical screening of a patient’s cancer for biomarkers is useful toward informing 
treatment decisions. As an example, breast cancer screening will typically include 
identification of the presence or absence of estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2), with HER2 
amplification and overexpression indicative of negative clinical outcome and an 
increased chance of recurrence [6]. Further, identification of HER2- positive cancer 
commonly indicates that a patient would be more likely to benefit from HER2-





Similarities in genetic mutations in cancer often exist across tissues, which has led to 
the emergence of more personalized medicine-based approaches emphasizing a 
cancer’s particular biomarkers to inform treatment decisions [7]. Yet, careful 
consideration of both the tissue of origin and cancer biomarkers is important toward 
identification of an appropriate therapy option [7]. 
1.2 ErbB receptor biology  
1.2.1 ErbB family overview  
Amongst potential targets for specific cancer therapies, the ErbB receptor family has 
attracted significant attention due to its ubiquity and prevalent role in mediating 
progression of numerous cancers. 
 
The ErbB family of transmembrane tyrosine kinase receptors (Figure 1.1) is 
composed of four members: the founding receptor epidermal growth factor receptor 
EGFR (HER1 - Human Epidermal Growth Factor Receptor 1), ErbB2 (HER2), 
ErbB3 (HER3), and ErbB4 (HER4). Each ErbB member has unique biological 
function; In mice, loss of any of the ErbB members results in lethality and based on 
the specific receptor loss, defects were found in tissues including brain, 
gastrointestinal tract, heart, lung, and skin [8]. The ErbB family is involved in 
complex signaling networks and is responsible for regulating cellular proliferation in 






Structurally, each ErbB receptor contains an extracellular domain, a single 
transmembrane spanning region, a cytoplasmic tyrosine kinase domain, and a C-
terminal phosphorylation tail [8,9]. ErbB2 is unique in that it has no known ligand 
and is constitutively available for heterodimerization with other receptors for 
activation [10]. ErbB3 is also unique in that it has a weak receptor tyrosine kinase 
(RTK) domain necessitating its partnership with other receptors for signal 
transduction [9,10].  
 
Generally, ErbB receptor signal transduction occurs at three levels of molecular 
interactions: first an activating ligand binds an ErbB receptor extracellular domain, 
second the active receptor undergoes a conformational change and dimerizes (or 
oligomerizes) with other active receptors, and third the intracellular tyrosine kinase 
domain of a dimerized receptor phosphorylates in trans the cytoplasmic tail of its 
dimerization partner leading to interaction with downstream effector proteins and 
signal transduction [11]. There are 12 known ligands that interact with the ErbB 
family members, some of which interact exclusively with one ErbB member, and 
others with specificity for multiple ErbB members [10,12]. Neuregulin-1β (NRG) is 
the native ligand for ErbB3 and ErbB4 [10]. Upon ErbB receptor activation, 
dimerization generally occurs amongst ErbB family members (Figure 1.1), although 
higher order oligomeric interactions and interactions with non-ErbB members have 
also been identified [10,13]. ErbB2 is the preferred heterodimerization partner for all 
other ErbB family members [14]. Generally heterodimerization, especially with 




Further, each ErbB receptor heterodimer pairing can achieve unique downstream 
signaling effects [10]. After complex signal processing events, ErbB-mediated signal 
transduction ultimately controls cellular responses such as apoptosis, migration, 






Figure 1.1: The ErbB receptor family This receptor family is composed of 4 members: EGFR 
(HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4) [10]. ErbB2 has no known ligand and is 
constitutively active for dimerization [10]. ErbB3 has a weak RTK domain necessitating its partnership 
with other receptors for signal transduction [10]. NRG is the native ligand for ErbB3 and ErbB4 [10]. 
Upon activation, the ErbB family members interact via dimerization for signal transduction [10]. Each 
ErbB receptor pairing can achieve unique downstream signaling effects [10]. ErbB2 homodimers and 
ErbB3 homodimers are not known to have physiological signaling significance [10].  
1.2.2 ErbB3 receptor biology  
ErbB3 receptors tend to exist as inactive oligomeric complexes in the absence of 
ligand, which become disrupted upon NRG binding [15]. ErbB3’s weak tyrosine 
kinase domain necessitates partnership of ErbB3 with other receptors for signal 
transduction [10]. After ligand-mediated activation, ErbB3 is readily available for 




ErbB2/ErbB3 heterodimer is the most potent oncogenic unit of the entire ErbB family 
[12]. Despite its weak tyrosine kinase domain, ErbB3 uniquely contains six consensus 
phosphotyrosine sites on its C-terminal tail that when phosphorylated in trans allow 
for signal transduction through docking of the p85 subunit of the effector molecule 
phosphatidylinositide 3-kinase (PI3K), which then leads to downstream activation of 
protein kinase B (Akt) [9]. The PI3K/Akt axis leads to downstream activation of the 
following effector molecules: NF-KB, P27, BAD, GSK3B, and mTOR, which 
ultimate allows for regulation of apoptosis, cell cycle, survival, and proliferation [9].  
 
ErbB3 (HER3)-mediated signaling through the PI3K/Akt axis is implicated in a 
variety of cancers including breast, ovarian, lung, and prostate [9], and HER3 
signaling can be classified as either ligand-dependent or ligand-independent. 
Following the aforementioned signaling cascade, ligand-dependent signaling is 
initiated by NRG binding to HER3, which activates the receptor for dimerization. 
Ligand-dependent HER3 signaling is a key driver of cancer proliferation in some 
cancers [16]. In subsets of advanced-staged ovarian cancers, the presence of a 
NRG/HER3 autocrine loop has been documented to drive cancer proliferation, and 
treatment with HER3-targeted antibodies or knockdown with HER3-targeted siRNA 
reduced cancer cell proliferation in vivo [16] suggesting potential oncogenic addition 
to this autocrine loop. In this study by Sheng et al., 4 of 7 tumor samples from 
patients with advanced-stage ovarian cancers revealed activated HER3 that 





Beyond NRG-mediated activation, ligand-independent HER3 activation has been 
reported especially in cases with HER2 overexpression. As addressed in more detail 
in section 2.3, inactive HER3 is in equilibrium between a locked and open 
conformation, whereby the open conformation facilitates dimerization; NRG binding 
to HER3 is thought to stabilize this open conformation [8]. Thus, overexpression of 
HER2 can reasonably increase the likelihood of heterodimerization with an openly 
conformed HER3 that has not been activated by NRG. In cancers with HER2 
amplification, HER2/HER3 heterodimerization still readily occurs, and HER2 
overexpression can drive ligand-independent HER3-mediated mitogenic signaling 
[17].  
1.2.3 HER3 extracellular domain structure  
The 620 amino acid extracellular region of HER3 is composed of four domains 
(Figure 1.2), organized as a tandem repeat of a two domain unit [8]. Domains I and 
III are beta helical and are involved with ligand binding specificity; Domains II and 
IV are cysteine rich [8,9]. In its locked conformation, HER3 contains an interdomain 
tether between domains II and IV, which results in a large pore circumscribed by 
domains II, III, and IV (Figure 1.2) [8]. This tether is formed by a main-chain/main-
chain hydrogen bond and three side-chain/side-chain interactions [8]. The inter-
domain tether is conserved among HER3 and HER4, both of which are activated by 
the native ligand NRG, but this feature is not present in HER2, the constitutively 








Figure 1.2: HER3 extracellular region structure: A. HER3 cartoon schematic B. HER3 surface 
schematic. The HER3 extracellular region is composed of four domains: I (blue), II (green), III 
(yellow), and IV (red); N- and C-termini are labeled in A and are respectively located in Domains I 
and IV. The HER3 extracellular region is depicted in a locked conformation with inter-domain tether 
contacts between domains II and IV causing the large pore encircled by domains II, III, and IV. NRG 
binding at the NRG binding pocket depicted in B stabilizes an open conformation of HER3 (not 
depicted); in its open conformation, the interdomain tether contacts between domains II and IV are 
released, thus making HER3 available for dimerization. In its open form, dimerization contacts exist 
on domains II. In its full transmembrane form, the C-terminus depicted in domain IV is connected to 
the transmembrane domain followed by the intracellular domain. This schematic was adapted from 
protein data bank file 1M6B and figures from Cho et al [8]. 
HER3 is known to adapt a variety of conformations, as a result of flexibility between 
extracellular domains II and III [8]. In its inactive state prior to ligand binding, HER3 
receptors are in equilibrium between a locked and open conformation, whereby the 
locked conformation typically exists on the cell surface as a monomer and the open 
conformation allows for the formation of inactive dimers and oligomers [18]. In its 
closed conformation, the NRG binding site is located within the pocket surrounded by 
domains I, II, and III (Figure 1.2B) [8]. Domain I was validated to have a binding site 
for HER3 via proteolytic cleavage analysis, and a truncated HER3 extracellular 
region composed of domains I and II binds NRG but with 30-fold lower affinity than 
the complete four domain extracellular region [8]. Binding of NRG to HER3 




ErbB family members [18]. In HER3’s open conformation, the interdomain tether 
between domains II and IV is released, making HER3 available for dimerization via 
contacts exist on domain II [19,20]. 
1.2.4 HER3-mediated resistance 
HER3 activation and overexpression is a key mediator of cancer cell resistance to 
targeted therapies via compensatory survival signaling [21–27]. HER3-mediated 
resistance has been found to compensate for inhibition of both “horizontal” and 
“vertical” signaling pathways, which respectively refer to signaling lateral to HER3 
by receptors such as HER2 or Axl, and signaling immediately downstream of HER3 
via effectors such PI3K/Akt [23,26–28] as will be elaborated on in section 5.4.  
1.3 Multivalency principles for molecular design  
1.3.1 Multivalency in the clinic 
Multivalency, the phenomenon by which a single molecule can be involved in 
multiple simultaneous molecular recognition events, is a promising concept toward 
the design of pharmaceuticals with enhanced efficacy by means of improved avidity, 
residence time, selectivity, and differential receptor trafficking [29–33]. The typical 
engineered multivalent molecule includes multiple binding moieties connected by a 
spacer domain (Figure 1.3). Both the binding domains and spacer domain can 






Naturally, multivalency has been effective in biological systems; take for example the 
immune defense molecule the antibody; the typical IgG is inherently bivalent. 
Surprisingly, the translation of multivalent engineering principles to the clinic is 
limited and has only recently emerged. The microbicidal dendrimer VivaGel, 
targeting bacterial and viral surfaces, is currently in stage III clinical trial [34], and 
the tetravalent bi-specific antibody MM-141, targeting IGF1R and HER3 has been 
designated as an orphan drug [35].  
1.3.2 Avidity effects and multivalent binding kinetics  
Engineered multivalency has profound implications in drug discovery, whereby low 
affinity binding domains can be engineered into high avidity multivalent ligands, 
abating the need for time-intensive processes of iterative molecular screening and 
redesign to enhance monovalent ligand affinity [30]. The expected enhancement in 
efficacy for multivalent ligands as compared to their monovalent counterparts is 
fundamentally explained by an increase in apparent affinity by means of increased 
effective concentration, a phenomenon known as avidity [30]. In a multivalent 
system, the monovalent affinities can synergize to promote the probability of 
subsequent binding following an initial event (Figure 1.3) [30]. Furthermore, the 
dissociation rate for a multivalent ligand is decreased compared to a monovalent 
analog [29,30,33]. A bivalent ligand in a monovalently bound state has the propensity 
to re-establish a bivalent interaction as opposed to complete molecular dissociation, 
which is illustrated in Figure 1.3B by a shift from State 2 to State 3 as opposed to a 
shift to State 1. Notably, Vauquelin et al. show through mathematical simulations that 




whereby multivalent ligands show increased residence time at the target, and a longer 
lasting therapeutic effect [33]. With regard to limitations and design considerations, 
the authors caution that multivalent therapeutics may take longer to reach 
equilibrium, and may not have sufficient time to equilibrate in vivo, thus the expected 
efficacy of multivalent ligands might not scale directly to experimental values [33].  
 
 
Figure 1.3: Increased valency enhances residence time and effective concentration. A. 
Monovalent ligand binding rate can be described by dissociation constant Kd. B. A bivalent ligand 
with two identical binding domains linked by a flexible spacer molecule exhibits differential kinetics 
compared to A. Upon monovalent binding of a bivalent ligand to a target receptor (State 2), the 
unbound ligand is brought effectively close to its target assuming adequate overexpression of the target 
receptor [30]. Bivalent binding events (State 3) accumulate and effective concentration is enhanced if 
Kd’ < Kd [30]. This schematic was based on drawings from Liu et al. [30] 
 
1.3.3 Linker domain considerations  
Although the linker domain in a multivalent molecule theoretically does not bind or 
interact with the therapeutic target, it is a key aspect of multivalent ligand design 
based on thermodynamic considerations [30]. Specifically, the parameters of linker 
stiffness, length, and geometry may impact therapeutic function and should be 
considered in molecular engineering design [30]. The optimal choice for these 
parameters depends greatly on the specific application, and the knowledge available 




and fixed, a rigid spacer that geometrically allows for unconstrained multivalent 
binding might be advantageous; rigid linkers are more entropically favorable for 
binding events [29,30].  However, flexible linkers have also proven effective in a 
variety of multivalent ligand designs [36]. A flexible spacer has the advantage of 
sampling a greater space, increasing the probability of multivalent binding [30]. 
However, ligand binding impairs the rotational and conformational freedom of the 
flexible linker, and therefore has a higher entropic cost compared to rigid linkers [30]. 
Yet, the enthalpic benefit of multivalent ligand binding will often offset this entropic 
penalty, thus allowing an avidity affect [30]. Linker domain length is another 
important parameter in multivalent ligand design. Various computational and 
experimental models have been developed to explore the influence of linker length 
and flexibility [36,37].  Theoretically, the longer and more flexible the linker, the 
greater the entropic cost for multivalent binding events [30]. Interestingly, 
Krishnamurthy et al. find that the theoretical penalty for these entropy losses is much 
lower than previously hypothesized based on their model system of a ligand tethered 
to the surface of a protein by a poly (ethylene glycol) linker [36]. The authors argue 
that a flexible spacer much longer than the necessary length to simultaneously bind 
multiple target sites is advantageous for multivalent ligand design given their 
unexpected finding that effective molarity is only weakly dependent on linker length 
[36].  
1.3.4 Selectivity in multivalent engineering design   
Beyond improved apparent affinity for target cells, increased ligand valency is 




ligand bound to a target cell versus ligand bound to a non-target cell [30]. Selectivity 
is especially important for systemic delivery applications, whereby a drug with 
improved selectivity will likely have enhanced efficacy and reduced off-target effects. 
Considering ligand binding to a surface receptor overexpressed on cancers cells and 
expressed at low levels on healthy cells, a monovalent ligand will theoretically show 
no preference for the receptors on the cancer cell, and thus if the receptors are 
overexpressed on the cancer cells by two-fold, the monovalent ligands will bind the 
cancer cells twice as frequently. A multivalent ligand, however, is expected to exhibit 
a higher degree of specificity compared its monovalent counterparts. Assuming the 
first binding event between a ligand and a target will be kinetically similar across 
valencies, then when a target is expressed at low levels, monovalent interactions will 
dominate, even when multivalent ligands are employed [30]. But when the target is 
overexpressed, subsequent binding events after the docking of multivalent ligands 
will exhibit an enhanced avidity effect based on the aforementioned differential 
binding kinetics (Figure 1.3), and therefore show greater selectivity for a target 




Figure 1.4: Multivalent ligands enhance selectivity. When bivalent ligands are deployed against a 
cancer cell with target overexpression, bivalent binding events dominate leading to enhanced residence 
time and avidity effects [30].  The bivalent ligands show preference for the receptors on the cancer cell 




on the healthy cell due to an inadequate level of surface receptors [30]. Schematic based on drawings 
from Liu et al. [30] 
1.3.5 Cautionary multivalent design considerations 
Notably, maximum binding moiety affinity is not always optimal in multivalent 
ligand engineering especially when considering selectivity; instead optimal selectivity 
is dictated by a careful balance between low monovalent constituent affinity, and high 
avidity of the multivalent molecule as a whole [30]. Likewise, extreme ligand affinity 
might not be ideal for trafficking through tumor vasculature.  In the phenomenon of 
the “binding site barrier”, antibodies with very high affinity bind strongly to the first 
tumor antigens located and accumulate heterogeneously throughout the tumor, 
primarily in the peri-vasculature region which leads to suboptimal efficacy [33,38]. 
Thus, optimal monovalent affinity and multivalent apparent affinity should be 
carefully considered and can be modulated by valency and appropriate binding 
moiety selection. Overall engineered multivalency provides a powerful tool for 
enhanced therapeutic efficacy in pharmaceutical design.  
1.4 ErbB-family targeted therapeutics 
1.4.1 FDA approved ErbB family-targeted therapies 
Targeting the ErbB family of receptor tyrosine kinases, which includes EGFR, HER2, 
HER3, and HER4, has been of clinical interest for more than two decades with an 
initial focus on targeting HER2 and EGFR. Generally, the HER family of 
transmembrane receptors contain an extracellular ligand binding domain targetable by 
antibody-based approaches, and an intracellular RTK domain targetable by small 
molecule therapeutics. Several monoclonal antibody based approaches have received 




targeted monoclonal antibody, and cetuximab and panitumumab, two EGFR-targeted 
monoclonals [39]. Several small molecules drugs that interact with the intracellular 
ATP binding pocket thus inhibiting RTK function have also gained FDA approval 
including EGFR targeted gefitinib and erlotinib, dual EGFR and HER2 targeted small 
molecule lapatinib, and more recently HER2 targeted neratinib (approved in 2017) 
[40].  
1.4.2 Antibody-based approaches against HER3  
HER3 has emerged as a therapeutic target in a variety of cancers including ovarian, 
prostate, breast, and lung [41], with HER3 expression occurring in 36-90% of breast 
cancers, and HER3 overexpression occurring in 16% of ovarian cancers [19]. 
 
Despite the significant clinical need to combat HER3-related mitogenic effects, no 
current HER3-targeted therapeutics have been FDA approved [42] and only the 
bispecific anti-HER3 anti-insulin like growth factor receptor 1 (IGF-IR) antibody 
MM-141 has been designated with orphan drug status (treatment of pancreatic 
cancer) [35]. HER3 structurally has a weak RTK domain, thus small molecule 
inhibitors disrupting RTK function are not considered an appropriate targeting 
strategies. Despite this weak RTK domain, HER3 is a key node in the ErbB signaling 
network forming potent mitogenic heterodimers with HER2 [12], activating survival 
signaling through the Akt/PI3K pathway [43,44], and serving as a mechanism of 
cancer resistance to targeted therapies through its overexpression and alternative 
activation [21–25,45]. Targeting HER3 is of significant clinical interest with several 




bispecific approaches [19], and various peptide and protein-based targeting strategies 
under investigation [46–50].  
 
The fully humanized HER3-targeted monoclonal MM-121 is currently in phase 2 
clinical trial in combination with the anti-mitotic chemotherapeutic docetaxel or 
replication and transcription inhibitor pemetrexed for the treatment of non-small cell 
lung cancer in which patients are selected for treatment based on NRG expression 
profile [51]. In previous work, Merrimack Pharmaceuticals demonstrated high 
heregulin-1β expression is positively correlated with cancer susceptibility to MM-121 
therapy, whereas other biomarkers including HER3, HER2, and EGFR expression 
have limited predictive value [43]. Mechanistically, the efficacy of MM-121 is at 
least in part due to inhibition of NRG-mediated HER3 activation, presumably by 
steric blockade of the HER3’s NRG-binding site. Interestingly, MM-121 treatment 
led to HER3 receptor downregulation in some cell lines (e.g. MALME 3M) but not 
others (e.g. DU145) and the specific mechanism of downregulation was unknown 
[43]. MM-121 showed limited efficacy and minimal pHER3 inhibition in cell lines 
with ligand-independent HER3 activation such as the HER2 amplified BT474 breast 
cancer cell line [43].  
 
Mechanistically, the design of antibodies to target HER3 is not limited to inhibition of 
NRG-mediated activation. Design of the fully human HER3-targeted antibody 
LJM716, currently in phase 1 clinical trials in HER2 positive tumors, was informed 




independent manners with the latter occurring predominantly by HER3 activation in 
trans in cancers with HER2 overexpression [17,34]. LJM716 does not does not 
prevent NRG binding to HER3, but instead locks HER3 into an inactive conformation 
that prevents HER3 interaction with its preferred dimerization partner HER2 [17]. 
LJM716 showed efficacy in various tumor models and also reduced proliferation in 
combination with the HER2-targeted monoclonal trastuzumab [17].   
 
Optimized immune effector function is another strategy to improve the therapeutic 
efficacy of HER3 targeted therapies. The humanized anti-HER3 monoclonal antibody 
RG7116, currently in Phase I clinical trial in combination with various ErbB-targeted 
therapeutics for the treatment of breast, non-small-cell lung cancer, and various solid 
tumors, has a glycoengineered FC domain that enhances antibody-dependent cell-
mediated cytotoxicity (ADCC) [34,52,53]. Like LJM716, RG7116 locks HER3 into 
an inactive conformation preventing both NRG-mediated HER3 activation, and 
heterodimer formation [52].   
 
Bispecific antibody-based approaches are also being exploited to treat HER3-
mediated malignancies by inhibiting specific dimerization partnerships. MM-111, a 
bispecific antibody for HER2 and HER3, failed clinical trials for the treatment of 
several HER2 positive cancers in combination with trastuzumab and paclitaxel [54]. 
Despite the aforementioned clinical trial results, MM-111 showed potent anti-tumor 
activity in vivo in several xenograft models, and mechanistically has advantages for 




that HER2 is commonly overexpressed to a much greater degree than HER3 and thus 
antibody docking to HER2 receptors on the cancer cell surface can subsequently 
increase the effective concentration of MM-111’s HER3-binding domain for 
enhanced HER3 blockade [55].  HER3 dimerization and oligomerization partners are 
not limited to ErbB family members. The design of MM-141, a tetravalent antibody 
with bispecificity for HER3 and IGF-IR, is informed by reports of a 
HER2/HER3/IGF-IR trimeric interactions responsible for trastuzumab resistance in 
some breast cancer cell lines [56]. Orphan drug MM-141, currently in phase II 
clinical trials in combination with chemotherapeutics nab-paclitaxel and gemcitabine 
for the treatment of metastatic pancreatic cancer in patients with the identified 
biomarker of high IGF-1 [51], strategically blocks the PI3K/AKT/mTOR signaling 
axis that is redundantly and compensatorily activated by HER3 and the structurally 
similar IGF-IR [56].  
 
1.4.3 Non-antibody scaffolds and next-generation antibody therapeutics  
Antibody approaches are limited by size, stability, and the ability to effectively 
penetrate tissues [57] as these molecules are high molecular weight, rely on multiple 
domains, disulfide bonds, and complex glycosylation patterns [58]. Further, antibody-
based therapies have shown limited efficacy, for example, HER2-targeted therapies 
typically show efficacy in ~24%-64% of patients with HER2-overexpressing tumors 
[59], and thus new approaches with improved efficacy and novel mechanisms of 
action are of clinical interest. Peptide and antibody fragment-based approaches 




easier manufacturability [57]. By employing low molecular weight binding moieties 
or antibody fragments, tethered multivalent ligands can be engineered for the design 
of custom therapeutics with control over half-life, tissue penetration, specificity, 
valency, affinity, and avidity [60]. Pharmaceutical companies such as Boehringer 
Ingelheim have engaged in blockbuster deals toward research and development on 
these next generation multivalent binding-fragment based approaches [61]. 
 
Similar to antibody fragments, affibody molecules provide an alternative scaffold for 
the development of high-affinity binding proteins. The affibody refers to a 58 amino 
acid, cysteine-free, three-helix bundle motif derived from the B-domain of 
staphylococcal protein A [58]. The B-domain was mutated for enhanced stability and 
this derivative is known as the Z-domain [58]. Affibodies have high stability and 
solubility as well as good tissue penetration, marking them as emerging scaffolds for 
therapeutic and imaging applications [46,58]. The affibody scaffold is highly 
amenable to phage display for the generation of high affinity binding molecules, and 
has demonstrated advantages over antibody fragments with regard to ease of 
molecular display [46,58]. Both monospecific and bispecific affibodies have been 
engineered for high-affinity to ErbB family receptors including ABY-025, a 
radiolabeled HER2 specific affibody currently in Phase II clinical trials for positron 
emission tomography imaging of breast cancer [46,49,50,57,58,62]. Therapeutic 
HER3 specific affibodies that block ligand-mediated HER3 activation and reduce 
cancer cell survival in vitro have been engineered with sub-nanomolar affinity 




further matured to low picomolar affinity through alanine scanning-based approaches 
[49]. Additional HER3 binding proteins include a bispecific albumin binding domain 
designed for improved half-life [48], and a HER3-specific surrobody, derived from a 
pre-B-cell receptor complex that inhibited both ligand-independent and ligand-
dependent HER3 signaling and proliferation, and showed efficacy in vitro and in vivo 
[47].   
 
Antibody fragments and low molecule weight proteins also have limitations 
compared to full-length monoclonal antibodies in that these scaffolds often have 
shorter half-lives, increased clearance due to reduced size and they inherently lack 
immune effector function [63]. To overcome these limitations, fusion with albumin-
binding proteins or PEGylation can enhance half-life [48,64]. Beyond protein-based 
strategies to target HER3, aptamer-based approaches against HER3 have also been 
developed [65]. With their low molecular weight, aptamers achieve many of the same 
advantages of fragment-based approaches including improved tissue penetration, but 
unmodified aptamers are limited by rapid clearance and degradation in the serum, and 
have received less developmental focus due to intellectual property restrictions [66].  
1.5 Opportunities and novel mechanism-based approaches against HER3 
 
While it is probable that some of aforementioned HER3-targeted approaches will 
emerge as effective therapeutics, either alone or in combination with other drugs, 
these approaches are still likely to be ineffective on a significant proportion of 




show efficacy in ~24%-64% of patients with HER2-overexpressing tumors [59], thus 
highlighting the need for novel therapeutic approaches to target HER3.  
 
1.5.1 HER3 sequestration-based approaches 
HER3 sequestration by engineered multivalent ligands is an innovative approach 
whereby HER3 is locked into non-signaling homotypic interactions (Figure 1.5) 
promoted by the tendency of HER3 to exist predominantly in clusters of pre-formed 
homotypic dimers or oligomers on the cell surface prior to ligand stimulation [67]. 
Proof-of-concept for HER3 sequestration was demonstrated by Jay et al. using an 
engineered bivalent Neuregulin-1β (NRG) molecule, which led to reduced 
proliferation and chemokinesis, and increased apoptosis in multiple cancer cell lines 
[68,69]. Treatment with bivalent Neuregulin-1β (NRG) reduced HER3, Akt, and 
HER2 phosphorylation, presumably by sequestering HER3 to homotypic interactions 
and thereby limiting interactions with its preferred dimerization partner HER2; these 
phenomena were in direct opposition to treatment with native monovalent NRG, 






Figure 1.5: ErbB3 sequestration by bivalent ligands: Multiple ErbB3 binding domains linked by a 
flexible spacer domain can sequester ErbB3 into non-signaling homotypic clusters, which occur at a 
cost to natural NRG-activated ErbB2/ErbB3 mitogenic heterodimer formation [68,69]. HER3 
sequestration was demonstrated to reduce cancer cell proliferation and chemokinesis [68]. Schematic 
adapted from Jay et al. [68]. 
1.5.2 Induced HER3 degradation and differential trafficking 
Upon ligand binding, EGFR is traditionally endocytosed and degraded [10]. On the 
contrary, the other ErbB members are more commonly recycled [10]. HER3 is 
constitutively recycled back to the cell surface, and heterodimerization with HER2 
reduces the HER3 internalization rate and increases the HER3 recycling rate [10], 
thus HER3 degradation represents a mechanistic strategy to inhibit HER3-mediated 
mitogenic signaling [19,30,43]. Multivalent ligands have been documented to 
promote receptor degradation via induced receptor clustering and differential 
trafficking [30]. This phenomenon of HER3 degradation has been induced by 
antibody-based HER3-targeting strategies [19,43], which could be explained 
mechanistically by bivalent binding of a HER3-targeted IgG antibody to two HER3 
receptors as an initiator of the process [19]. In traditional receptor degradation 
processes, the receptor is first ubiquitin-tagged and then traffics to either the 





1.5.3 Targeting the ErbB family with multiple binding epitopes   
Targeting the ErbB family members with multiple antibody epitopes has 
demonstrated enhanced therapeutic efficacy compared to monoclonal antibody 
treatment in a variety of cancer models [13,71,72]. MM-151, an oligoclonal antibody 
that binds multiple regions of the EGFR extracellular domain, is designed to 
overcome EGFR mutation-mediated resistance, and has proved beneficial especially 
where monoclonal approaches have failed [13]. MM-151 is currently in clinical trials 
for the treatment of a variety of solid tumors including colorectal cancer [34]. Two 
monoclonal antibodies specific against HER3 enhanced therapeutic efficacy in 
combination with BRAF/MEK inhibitors and prevented BRAF inhibition resistance 
for the treatment of melanoma [72]. Likewise dual treatment with HER3 monoclonal 
antibodies specific for domain I and domain III of the ECD of HER3 enhanced 
efficacy in vitro and in vivo in NCI-N87 gastric carcinoma compared to either 
monoclonal treatment alone; dual treatment with these antibodies led to inhibition led 
to potent blockade of ligand-dependent and ligand-independent HER3 signaling [71]. 
Overall, targeting an ErbB receptor with multiple antibodies specific for unique 
epitopes of the extracellular domain has shown enhanced therapeutic efficacy in 
cancers with and without documented ErbB mutations and thus this strategy could 
show broad utility and be especially beneficially in cancers with ErbB oncoprotein 
mutations [71,72]. EGFR mutations in cancer are common, occurring in 20% of 
colorectal cancers [13]. Likewise, Jaiswal et al. identified protein altering HER3 




lung cancer (NSCLC) (adeno; 1/71), and 1% of NSCLC (squamous; 1/67) cancers 
[41]. 
 
1.5.4 HER3-targeting for combination therapies  
HER3 compensatory signaling is a critical mediator of cancer cell resistance to 
targeted therapies and thus “vertical” and “horizontal” combination approaches 
involving HER3-targeted therapeutics are a clinical need for improved cancer 
therapies [21–27].   
 
Tumors previously susceptible to “horizontal” EGFR and HER2 tyrosine kinase 
inhibitors have been reported to grow refractory to such therapies via HER3 
overexpression and an equilibrium shift in HER3 phosphorylation [23]. Likewise, 
cancer therapies targeting the Axl receptor tyrosine kinase, an aggressive driver of 
cancer growth through activation of the PI3K/Akt, ERK, and NF-κβ, are limited by 
acquired resistance and compensatory alternative HER3 activation [28]. Torka et al. 
demonstrated that treatment of OvCAR8 and MDA-MB-231 cells with small 
molecule Axl/Met-related tyrosine kinase inhibitor BMS-777607 leads to increased 
HER3 expression and NRG-dependent HER3 phosphorylation [28].  
 
The “vertical” PI3K/Akt axis has been regarded as a redundant and promiscuous 
signaling pathways involving a variety of escape routes and positive feedback 
mechanisms to evade targeted therapy [26,27]. The use of small molecules to target 




including ovarian, breast, and prostate [26,27]; for example the Akt inhibitor 
MK2206 and the PI3K I inhibitor BMK120 are in clinical trials for the treatment of 
ovarian cancer [21,26]. However, these small molecule drugs have limited efficacy 
due to compensatory signaling and alternative activation of other RTKs [21,26,27]. 
Likewise, prostate cancers with acquired resistance to PI3K inhibitors are often 
characterized by elevated NRG expression, and antibodies against HER2/HER3 have 
further been demonstrated to improve efficacy in prostate cancers refractory to PI3K 
inhibition [21]. 
Chapter 2: Affibody Design, Characterization, and Purification  
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2.1 Introduction 
 
HER3, a member of the ErbB receptor tyrosine kinase (RTK) family, which also 




emerged as a therapeutic target in ovarian, prostate, breast, lung and other cancer 
subtypes [41]. HER3 is unique in the ErbB family in that it has a weak tyrosine 
kinase domain [10,73], necessitating its partnership with other ErbB members for 
downstream signal transduction. Despite this, HER3 is a key node in the ErbB 
network, characteristically dimerizing with HER2 or other partner receptors (e.g. c-
MET, EGFR) to mediate cancer progression and/or metastasis [44]. Structurally, 
HER3 contains six phosphotyrosine sites in its C-terminal tail [9,74,75], allowing for 
potent mitogenic signaling through the PI3K/Akt pathway. Further, HER3 activation 
can enable acquired resistance to cancer therapeutics, including ErbB-targeted drugs 
[21–25,45].  
 
Numerous monoclonal antibody (mAb) approaches directed at HER3 are in 
development [19], and it is probable that some of these will continue to emerge as 
effective therapeutics, either alone or in combination with other drugs. However, 
these approaches are still likely to be ineffective in a significant proportion of 
patients; for example, FDA-approved HER2-targeted therapies have been reported to 
show efficacy in ~24%-64% of patients with HER2-overexpressing tumors [59]. 
Thus, development of alternative therapeutic approaches against HER3 as part of 
anti-tumor targeting strategies, particularly where HER3 acts as a facilitator and 
modulator of oncogenic signaling cascades, would fill a critical clinical need.  
 
Towards meeting this need, one promising concept for improved design of 




biology and protein engineering approaches. Multivalency refers to the phenomenon 
by which a single molecule can be involved in multiple simultaneous molecular 
recognition events, which is hypothesized to enhance therapeutic efficacy by means 
of improved avidity, residence time, selectivity, and differential receptor trafficking 
[29–33]. The therapeutic potential of multivalent ligands against HER3 specifically is 
supported by the possibility of inducing HER3 sequestration by engaging HER3 into 
non-signaling homotypic interactions. This phenomenon may be promoted by the 
tendency of HER3 to exist predominantly in homotypic clusters on the cell surface 
prior to ligand stimulation [67]. Our previous work demonstrated the therapeutic 
potential of multivalent HER3 engagement by using an engineered bivalent 
Neuregulin-1β (NRG) molecule, which induced decreased proliferation and 
chemokinesis and increased apoptosis in multiple cancer cell lines [68,69]. However, 
employing NRG as a HER3-binding domain is problematic from a translational 
perspective, as it could activate HER3 to induce pro-neoplastic signaling [16,76,77]. 
The therapeutic potential of bivalent NRG is further limited by potential off-target 
effects on HER4 as well as challenges in protein production due to aggregation 
caused by sequence repetition and improper formation of multiple disulfide bonds.   
 
Thus, in this work, we sought to extend the concept of multivalent HER3 engagement 
by employing HER3-binding domains with greater translational potential and lower 
risk of pro-neoplastic side effects. Utilizing the Z05413 affibody – a 58 amino acid 
blocking peptide with sub-nanomolar affinity to HER3 developed by Lofblom and 




HER3 ligands and evaluated their functional efficacy in multiple cancer cell lines in 
comparison to monovalent molecules. We further investigated the relevance of the 
specific molecular conformation employed as well as the mechanisms contributing to 
the efficacy of the multivalent ligands. Our results indicate that multivalency 
enhances HER3 signaling inhibition and induces rapid downregulation of the receptor 
by affibody molecules, further establishing multivalent engagement of HER3 as a 
promising therapeutic strategy. 
2.2 Methods 
2.2.1 Protein production and purification 
Coding DNA sequences for affibody constructs were inserted into the pET45b vector 
(Merck Millipore) and Q5 Directed mutagenesis (New England Biolabs) was used to 
generate bivalent affibodies with varying domain size. pET45b-affibody constructs 
were transformed into Escherichia coli (E. coli) strain BL21 (DE3) (New England 
Biolabs). For protein expression, 500 mL LB broth with 100 µg/mL ampicillin was 
inoculated from a 3 mL overnight starter culture, incubated at 37o C, shaken at 220 
rpm, grown to an OD600 of 0.6-0.8, induced with 0.4 µM IPTG, and grown for 4 hours 
at 30oC. The cell pellet was isolated by centrifugation at 6000 rpm for 15 minutes and 
frozen at -20oC. Soluble protein lysates were generated using B-PER complete 
protein extraction reagent (Thermo Fisher Scientific) following manufacturer’s 
protocol and purified by immobilized metal affinity chromatography using TALON 
metal affinity resin (Clontech), and refined/buffer exchanged in PBS using ENrich 
SEC 650 size exclusion (Bio-Rad) high performance liquid chromatography NGC 




2.2.2 Protein molecular weight and sequence identity determination by mass 
spectrometry  
For molecular weight determination, monovalent, bivalent, and trivalent affibodies 
were mixed, and then separated with a ProSwift RP-4H monolithic column. Trivalent 
affibody spectrum was further analyzed with poroshell C3 microbore column. Mass 
spectra were acquired with a Thermo Scientific Orbitrap Fusion Lumos mass 
spectrometer at R=120,000 (m/z 200). Protein molecular weight was calculated using 
XTract. For sequence identity determination, monovalent, bivalent, and trivalent 
affibodies were diluted with 0.1 M triethylaminebicarbonate (TEAB) and digested 
with Trypsin/LysC Mix (Promega V5073) at 35°C overnight. Digest was acidified 
with glacial acetic acid and analyzed by NanoLC-MS/MS using a trap column 
(Thermo Scientific Acclaim PepMap™ 100, 5 µm, 100 Å, 300 µm × 5 mm) and an 
analytical column (Thermo Scientific Acclaim PepMap™ 100, 3 µm, 100 Å, 75 µm × 
250 mm). Data were processed using Proteome Discoverer (v 2.1) and Sequest HT. 
 
2.2.3 HER3 binding affinity determination by surface plasmon resonance  
Interactions between the affibodies and HER3 were analyzed by surface plasmon 
resonance using a Biacore T200 system (GE Healthcare). HER3 (Human, His-tagged; 
Sino Biological) at 50 µg/mL in Acetate 4.5 was covalently immobilized on a CM5 
chip via amine coupling to a final response of 1600 RU in 25 mM HEPES pH 7.3 at 
25°C. Affibody samples were prepared in degassed, filtered HBS-P+ buffer (GE 




(30 µL/min) of increasing concentration of affibodies (0.1-10 nM) passed over the 
sensor chip for 120 s association followed by 420 s dissociation. Following buffer and 
reference subtraction, kinetic constants and binding affinities were determined 
utilizing the Biacore T200 evaluation software (GE Healthcare).  
2.2.4 Cell lines and reagents  
The OvCAR8 cell line was obtained from Dr. Christina Annunziata (National Cancer 
Institute). Du145, BT474 and H1975 cell lines were purchased from ATCC. 
OvCAR8, Du145, and H1975 were maintained in RPMI 1640 (ATCC), BT474 cells 
were maintained in Hybri-Care Medium (ATCC). 
2.2.5 Cell signaling studies 
Cells were serum starved for 4 hours, treated with the indicated concentrations of 
affibody or the small molecule pan-HER kinase inhibitor N-(4-((3-Chloro-4-
fluorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)2-butynamide (Millipore 324840) 
(Total Inhibitor) for 30 minutes, stimulated with 10 nM human heregulin-1β (NRG) 
(Peprotech) for 10 minutes, lysed, and probed by immunoblot for pHER3, pHER2, 
pAkt, and pERK1/2. For immunoblotting, membranes were probed with primary 
antibodies (21D3 pHER3, tyr877 pHER2, D9E pAkt, pERK1/2 #9101, 13E5 β-actin, 
D65A4 β−tubulin) all from Cell Signaling, and secondary antibody IRDye 800 CW 
(Licor), and scanned using an Odyssey CLx image system (Licor).   
2.2.6 HER3 downregulation assays 
To examine HER3 levels, cells were treated with the indicated concentrations of 




control, lysed at the indicated time points, and probed by immunoblot for HER3 as 
previously described using primary antibodies (D22C5 HER3, and 13Ε5 β−actin).  
2.3 Results 
2.3.1 Engineered multivalency enhances affibody-induced pHER3 inhibition 
The general hypothesis motivating these studies is that engineered multivalency can 
enhance HER3-targeted therapeutic efficacy by means of enhanced avidity and HER3 
sequestration into non-productive homotypic interactions, given that hetero-
dimerization is requisite for HER3-mediated signal transduction. Thus, employing the 
Z05413 affibody [46] as the HER3 binding domain and a flexible protease resistant 
peptide spacer [68] as a linker domain, bivalent and trivalent HER3 affibodies were 
designed (Figure 2.1A). Multivalent affibodies were expressed as recombinant 
proteins in BL21 (DE3) E. coli and purified by immobilized metal ion 
chromatography and size exclusion chromatography (Figure 2.1B). All HER3 
affibodies consistently displayed molecular weights higher than their predicted values 






Figure 2.1: Multivalency enhances affibody-mediated pHER3 and pAkt inhibition. A. Schematic 
representing monovalent, bivalent and trivalent affibody constructs. B. Purified protein products are 
displayed on a Coomassie stained gel loaded at 7.3 mg/lane. Monovalent, bivalent, and trivalent 
ligands have respective theoretical molecular weights of 7.6, 19.1, 30.5 kDa. C. OvCAR8, Du145, 
H1975 and BT474 cells were treated with the indicated concentrations of trivalent, bivalent or 
monovalent ligand, or 100 nM pan HER kinase inhibitor (total inhibitor), or media alone (no 
treatment) for 30 minutes, then stimulated with 10 nM NRG for 10 minutes, lysed, and probed for 
pHER3, pAkt and b-actin by immunoblot. All multivalent ligand concentrations refer to the 
concentration of individual affibody domain. Results shown are representative of three independent 









































































Figure 2.2: Immunoblot quantification of Figure 2.1: Multivalency enhances affibody-mediated 
pHER3 and pAkt inhibition. Quantified pHER3 (left) and pAkt (right) values are displayed for A. 
OvCAR8 B. Du145 C. H1975 and D. BT474 cells. Blots were quantified using Odyssey CLx image 






loop-helix motifs [46]. However, mass spectrometry analysis indicated that all 
affibodies showed molecular weight and amino acid composition consistent with 
predicted values (Figures 2.3-2.5). Binding affinities for HER3 were characterized 
for all affibodies by surface plasmon resonance. Monovalent and bivalent affibodies 
had similar affinities to HER3 (monovalent KD = 316 pM, bivalent KD = 327 pM, 
mean values), whereas trivalent affibodies displayed substantially lower affinity 
(trivalent KD = 2340 pM) (Figure 2.6). These data suggest that any impact of 
multivalency on the cellular effects of HER3 affibodies is not due to enhanced HER3 
binding.  
 
The Z05413 affibody is reported to disrupt NRG-mediated HER3 signaling [46]. To 
assess the effect of multivalency on this phenomenon, cells were treated with the 
indicated equivalent concentrations of affibody domains (100 nM of monovalent 
affibody molecule has an equivalent affibody domain concentration to 50 nM of 
bivalent and 33 nM of trivalent affibody molecules), stimulated with NRG, and then 
probed for phosphorylated HER3 (pHER3) by immunoblot. The results indicate that 
multivalency enhanced affibody-mediated pHER3 signal inhibition in a variety of 
cancer cell lines – OvCAR8 (ovarian), Du145 (prostate), BT474 (breast) and H1975 
(lung) – which were selected based on the reported role of HER3 signaling in 
proliferative and/or metastatic phenotypes as well as in promoting drug resistance 
[16,22,43,78]. The most significant differential effects were seen between multivalent 
versus monovalent treatment groups (Figures 2.1C, 2.2); differences between the 






Figure 2.3: Mass spectrum of purified monovalent affibody confirms predicted molecular 
weight. Monovalent, bivalent, and trivalent affibodies were mixed, and then separated with a ProSwift 
RP‐4H monolithic column. Mass spectra were acquired with a Thermo Scientific Orbitrap Fusion 







Figure 2.4: Mass spectrum of purified bivalent affibody confirms predicted molecular weight. 
Monovalent, bivalent, and trivalent affibodies were mixed, and then separated with a ProSwift RP‐4H 
monolithic column. Mass spectra were acquired with a Thermo Scientific Orbitrap Fusion Lumos mass 








Figure 2.5: Mass spectrum of purified trivalent affibody matches predicted value. Monovalent, 
bivalent, and trivalent affibodies were mixed, and then separated with a ProSwift RP‐4H monolithic 
column. Trivalent affibody spectrum was further analyzed with poroshell C3 microbore column. Mass 
spectra were acquired with a Thermo Scientific Orbitrap Fusion Lumos mass spectrometer at 
R=120,000 (m/z 200). Protein molecular weight was calculated using XTract. Trivalent affibody is too 







Figure 2.6: Surface plasmon resonance analysis of affibody-ErbB3 interaction. Sensorgrams of A. 
Monovalent B. Bivalent and C. Trivalent affibody interactions with immobilized ErbB3. D.  Summary 
of binding constants (KD, Kd, Ka). Briefly, ErbB3 (50 µg/mL) was covalently immobilized on a CM5 
chip via amine coupling to a final response of 1600 RU. Single cycle kinetic experiments were carried 
out using five injections (30 µL/min) of increasing concentration of affibodies (0.1-10 nM) passed over 
the sensor chip for 120 second association followed by a 420 second dissociation. Following buffer 
and reference subtraction, kinetic constants and binding affinities were determined utilizing the 
Biacore T200 evaluation software (GE Healthcare).
 
 39 
2.1C, 2.2). Additionally, assessment of downstream signaling revealed that, in all cell 
lines tested, increased valency resulted in enhanced pAkt inhibition, with the most 
differential effects again seen between multivalent compared to monovalent treatment 
groups (Figures 2.1C, 2.2).  
 
One potential outcome of HER3 engagement by multivalent ligands is deprivation of 
productive dimerization with HER2, as observed for bivalent NRG in our previous 
work [68]. Thus, immunoblots for phosphorylated HER2 (pHER2) were performed, 
with the results indicating that pHER2 levels were not consistently affected by 
affibody treatments in the BT474 cell line relative to control (10 nM NRG) levels 
(Figures 2.7, 2.8A). Downstream pERK1/2 in this cell line was similarly not 
significantly affected by affibody treatments (Figures 2.7, 2.8B). Notably, pHER2 
was not detected by immunoblot in the OvCAR8, Du145, and H1975 cell lines after 
NRG stimulation (these cell lines are reported to have substantially less HER2 
expression compared to the BT474 cell line; Broad-Novartis Cancer Cell Line 
Encyclopedia). Previous reports indicate that monovalent HER3 affibodies inhibit 
NRG-induced pHER2 in MCF-7 and SKBR-3 cells [50,62]; the MCF-7 data match 
our own observations. Taken together, pHER2 inhibition by HER3 affibodies may be 






Figure 2.7: HER3 affibodies do not influence pHER2 levels regardless of valency in BT474 cells 
A. BT474 cells were treated with the indicated concentrations of trivalent, bivalent or monovalent 
affibodies, or 100 nM pan HER kinase inhibitor (total inhibitor), or media alone (no treatment) for 30 
minutes, then stimulated with 10 nM NRG for 10 minutes, lysed, and probed by immunoblot for 
pHER2, or pERK1/2. β-Tubulin levels were assessed for normalization purposes. Results shown are 
representative of two independent experiments. All blots were cropped. 
 
2.3.2 Multivalency induces increased affibody-mediated HER3 downregulation 
It has been reported that multivalent binding events can induce differential receptor 
trafficking [30]. Thus, the impact of multivalent affibodies on HER3 expression was 
investigated as a potential mechanism of their increased HER3 signaling inhibition 
compared to monovalent analogs. The results of these studies indicate that, in 
comparison to monovalent affibodies, both bivalent and trivalent affibodies more 
potently downregulate HER3 protein levels in all cell lines tested. Specifically, 
substantial HER3 downregulation was observed 3 hours after application of 10 nM 
equivalent doses of trivalent and bivalent affibodies compared to monovalent 
affibody-treated cells and untreated controls, and this effect persisted over 72 hours 







Figure 2.8: Immunoblot quantification of Figure 2.7: HER3 affibodies do not influence pHER2 
levels regardless of valency in BT474 cells. Quantified A. pHER2 and B. pERK1/2 values. Blots 
were quantified using Odyssey CLx image system (Licor) Analysis Tool and normalized to β-Tubulin. 








FIGURE 2.9: Multivalency induces affibody-mediated HER3 downregulation. A. OvCAR8 B. 
Du145 C. H1975 D. BT474 cells were treated with 10 nM trivalent, bivalent or monovalent affibody, 
pan HER kinase inhibitor (total inhibitor), or media alone (no treatment), lysed at the indicated time 
points, and probed by immunoblot for HER3. β-actin levels were assessed for normalization. Results 





Figure 2.10: Immunoblot quantification of Figure 5: Multivalency enhances affibody-mediated 
HER3 downregulation. Quantified HER3 values relative to normalized HER3 of no treatment control 
are displayed for A. OvCAR8 B. Du145 C. H1975 and D. BT474 cells. Blots were quantified using 
Odyssey CLx image system (Licor) Analysis Tool and normalized to b-actin. Results shown are 





2.3.3 Linker domain size has limited impact on bivalent affibody efficacy 
Linker domain size is reported to be an important parameter in multivalent ligand 
design [30]. The flexible, glycine rich, protease resistant spacer domain employed for 
the bivalent and trivalent affibodies described in Figure 2.11 contains 3 repeat units 
and has a predicted length of approximately 20 nanometers (nm), long enough to 
traverse the theoretical 10 nm distance required to sequester a cross-facing HER3 
homodimer [68]. To systematically investigate the role of linker domain size on 
efficacy, a panel of bivalent affibodies was engineered by varying the number of 
repeat units in the spacer peptide from 1 to 4 (each unit having a predicted length of 
~7 nm) (Figures 2.11A, B). Inhibitory efficacy against HER3 and Akt 
phosphorylation across multiple cell types with bivalent affibodies of various linker 
domain sizes was observed to be similar, with no consistent trends relating spacer 
domain length to inhibitory efficacy (Figures 2.11C, 2.12). Interestingly, the 
increased pHER3 inhibition associated with multivalency was still observed for the 
smallest linker size tested, suggesting that even lower MW multivalent HER3 
affibodies have enhanced therapeutic potential.  
2.3.4 Functional effects of bivalency can be achieved with a minimal 3-glycine linker 
Interestingly, we find that reducing the linker domain size to approximately 1 nm in 
length (three glycine residues) did not impair affibody-mediated pHER3/pAkt 
inhibition or HER3 downregulation (Figures 2.13, 2.14) as evaluated in OvCAR8 
ovarian cancer cells previously identified to be highly responsive to HER3 affibody 
therapeutics [79]. These results demonstrate that linker length (and by extension, the 





Figure 2.11: Linker domain size has limited impact on bivalent affibody activity. A. Schematic 
representing bivalent affibodies of varying linker domain size: 1 link (1 repeat unit), 2 link, 3 link, and 
4 link. B. Purified protein products of bivalent affibodies with the indicated linker domain size are 
displayed on a Coomassie stained gel loaded at 7.3 µg/lane. 1 link, 2 link, 3 link, and 4 link bivalent 
affibodies have respective theoretical molecular weights of 16.0, 17.5, 19.1, 20.6 kDa. C. OvCAR8, 
Du145, H1975, and BT474 cells were serum starved for 4 hours, treated with the indicated 
concentrations of trivalent, bivalent or monovalent affibody, pan HER kinase inhibitor (total inhibitor), 
or media alone for 30 minutes, then stimulated with 10 nM NRG for 10 minutes, lysed, and probed by 






Figure 2.12: Immunoblot quantification of Figure 2.11: Linker domain size has limited impact 
on bivalent affibody activity. Quantified pHER3 (left) and pAkt (right) values are displayed for A. 
OvCAR8 B. Du145 C. H1975 and D. BT474 cells. Blots were quantified using Odyssey CLx image 
system (Licor) Analysis Tool and normalized to b-actin. Results shown are averages of two 




HER3 ligand efficacy. A potential advantage of multivalent ligands utilizing a 
minimalistic linker may be their lower immunogenicity and higher translational 
potential compared to our first-generation bivalent affibodies, and therefore we 
moved forward with multivalent ligands incorporating a three-glycine linker for 





Figure 2.13: Linker length has limited impact on bivalent affibody-mediated pHER3 inhibition 
and HER3 downregulation. A. Schematic representing multivalent affibody constructs with 3 or 64 
amino acid (aa) linker size. B. Purified protein products are displayed on a Coomassie stained gel 
loaded at 10 mg/lane. Bivalent affibody with 3 aa linker and 64 aa linker ligands have respective 
theoretical molecular weights of 14.4 and 19.1 kDa. C. OvCAR8 cells were treated with the indicated 
concentrations of bivalent affibody 3 or 64 aa linker, or 100 nM pan HER kinase inhibitor (total 
inhibitor), for 30 minutes, then stimulated with 10 nM NRG for 10 minutes, lysed, and probed for 
pHER3, pAkt and b-actin by immunoblot. D. OvCAR8 cells were treated with 10 nM bivalent affibody 
with 3 and 64 aa linker, lysed at the indicated time points, and probed by immunoblot for HER3 and b-
actin. All multivalent ligand concentrations refer to the concentration of individual affibody domain. 




Figure 2.14: Immunoblot quantification of Figure 2.13.  Quantified A. pHER3 B. pAkt and C. 
HER3 values are displayed for Figure 1. Blots were quantified using Odyssey CLx image system 
(Licor) Analysis Tool and normalized to β-actin. Results shown are mean +/- SEM of three 




2.3.5 Hexavalent and bivalent HER3 affibodies show similar activity. 
We hypothesized that engineered multivalency could improve HER3 ligand 
bioactivity through enhanced avidity effects and HER3 sequestration. Previously, we 
compared the bioactivity of monovalent, bivalent, and trivalent affibody formats and 
observed that bivalent and trivalent ligands had comparable bioactivity with regard to 
pHER3/pAkt inhibition, and HER3 downregulation [79]. To more conclusively assess 
the impact of valency on affibody bioactivity, we examined the utility of hexavalent 
ligands in comparison to our bivalent ligands with three-glycine linkers (Figure 2.15 
A, B). We likewise observed that valency above two had limited impact on pHER3 
inhibition and HER3 downregulation (Figure 2.15C, D, 2.16). Thus, we focused 





Figure 2.15: Hexavalent and bivalent HER3 affibodies show similar activity. 
A. Schematic representing monovalent, bivalent, and hexavalent affibody constructs. B. Purified 
protein products are displayed on a Coomassie stained gel loaded at 10 mg/lane. Monovalent, bivalent, 
and hexavalent affibody constructs have respective theoretical molecular weights of 7.6, 14.4, and 41.6 
kDa. C. OvCAR8 cells were treated with the indicated concentrations of monovalent, bivalent, or 
hexavalent affibodies, or 100 nM pan HER kinase inhibitor (total inhibitor), or media alone (no 
treatment) for 30 minutes, then stimulated with 10 nM NRG for 10 minutes (except for no treatment 
negative control), lysed, and probed for pHER3, pAkt and b-actin by immunoblot. D. OvCAR8 cells 
were treated with 10 nM monovalent, bivalent, hexavalent linker, pan HER kinase inhibitor or media 
alone, lysed at the indicated time points, and probed by immunoblot for HER3 and b-actin. All 
multivalent ligand concentrations refer to the concentration of individual affibody domains. Results 




Figure 2.16: Immunoblot quantification of Figure 2.15. Quantified A. pHER3 B. pAkt and C. 
HER3 values are displayed for Figure 2. Blots were quantified using Odyssey CLx image system 
(Licor) Analysis Tool and normalized to β-actin. Results shown are mean +/- SEM of three 
independent experiments.  
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2.3.6 Arrangement of HER3 affibodies around an albumin-binding domain has 
minimal impact on bioactivity 
Affibodies, despite their advantages over mAbs such as increased tissue penetration, 
stability, and ease of manufacturing, have pharmacokinetic limitations that are likely 
to hinder their therapeutic efficacy in vivo [62]. Albumin-binding domain (ABD) 
fusions have been widely exploited to extend circulating half-life by increasing 
molecular hydrodynamic radius, enabling FcRn-mediated recycling, and reducing 
renal clearance [62,80–82]. We generated various monovalent and bivalent HER3 
affibody fusions with albumin-binding domains (Figure 2.17A, B). Specifically, we 
generated monovalent ligands HA and AH, and bivalent ligands HHA, HAH, AHH 
where ‘H’ denotes HER3 binding domain and ‘A’ denotes albumin-binding domain; 
molecular domains were connected by three-glycine minimal linkers. We selected 
ABD035 as the albumin-binding domain for this study [80]. The entire panel of HER3 
affibody ABD fusions retained bioactivity similar to unmodified affibodies with 
regard to pHER3/pAkt inhibition (Figure 2.17C, 2.18) and HER3 downregulation, 
both in the presence and absence of bovine serum albumin (Figure 2.17 4D, E, 2.18).  
The retained bioactivity of HHA and AHH molecules indicates that HER3 receptor 
engagement is efficient even with a centralized HER3 binding domain, and thus the 
possible increased risk of the centralized HER3 binding domain being sterically 
inhibited from HER3 binding was not observed. Given that ABD fusion location had 
limited impact on protein bioactivity, we selected monovalent HA and bivalent HHA 







Figure 2.17: Arrangement of HER3 affibodies around an albumin-binding domain has minimal 
impact on bioactivity. A. Schematic representing monovalent and bivalent albumin binding domain 
fusion constructs where H denotes HER3 binding domain and A denotes Albumin binding domain B. 
Purified protein products are displayed on a Coomassie stained gel loaded at 10 mg/lane. Monovalent 
ABDs HA and AH have respective theoretical molecular weights of 12.9 and 13.0 kDa, bivalent ABDs 
HHA, HAH, and AHH have M.W. of 19.7, 19.7, and 19.8 kDa respectively, and HH - bivalent HER3 
affibody positive control lacking ABD - has M.W. of 14.4 kDa C. OvCAR8 cells were treated with the 
indicated concentration affibody construct, or 100 nM pan HER kinase inhibitor (total inhibitor), or 
media alone (no treatment) for 30 minutes, then stimulated with 10 nM NRG for 10 minutes (except 
for no treatment negative control), lysed, and probed for pHER3, pAkt and b-actin by immunoblot. In 
the D. absence of bovine serum albumin (BSA), or E. presence of 35mg/ml BSA, OvCAR8 cells were 
treated with 10 nM of the indicated affibody construct, or media alone (no treatment), lysed at the 
indicated time points, and probed by immunoblot for HER3 and b-actin. All multivalent ligand 
concentrations refer to the concentration of individual affibody domains. Results shown are 






Figure 2.18: Immunoblot quantification of Figure 2.17 (pHER3 and pAkt). Quantified A., B. 
pHER3 and B., C. pAkt values are displayed for Figure 4. Blots were quantified using Odyssey CLx 
image system (Licor) Analysis Tool and normalized to β-actin. Results shown are mean +/- SEM of 
three independent experiments. 
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Figure 2.19: Immunoblot quantification of Figure 2.18 (HER3). Quantified A, B. HER3 values are 
displayed for Figure 4. Blots were quantified using Odyssey CLx image system (Licor) Analysis Tool 




2.4 Discussion  
 
HER3, a potent activator of the PI3K/Akt pathway [9], and a mediator of resistance to 
ErbB and non-ErbB targeted therapies [21–25,45], is an important target for cancer 
therapy [19]. New and improved HER3-targeted therapeutics would provide 
additional treatment options for patients with cancers refractory to current therapies. 
In this study, we demonstrated that engineered multivalency could enhance the 
therapeutic potential of HER3-targeted affibodies. Further, we identified multivalent 
ligand-induced HER3 downregulation as a potential mechanism of action that could 
be exploited by other HER3-targeted therapeutics. 
 
Cellular effects of various HER3 affibodies have previously been characterized, and 
the ability of monovalent affibodies to inhibit NRG-induced HER3 and Akt 
phosphorylation and cell growth is well established [49,50]. Bivalent and bispecific 
affibodies have also been described, with a bivalent HER3 affibody incorporating an 
albumin-binding domain shown to efficiently inhibit phosphorylation of both HER3 
and HER2 [62]. The studies presented here significantly extend these findings to 
show that therapeutically relevant advantages of HER3-targeted affibodies endowed 
by multivalency are robust across multiple cancer cell lines, potentially independent 
of linker domain identity, and potentially the result of enhanced HER3 
downregulation. These studies also extend our own previous work demonstrating the 
bioactivity of bivalent HER3 ligands [68,69], showing that multivalent engagement 
may be a generally useful strategy for HER3-targeted therapeutics that does not 
require employment of NRG. Given the potential for a NRG domain to initiate 
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undesired activation of HER3 as the result of unexpected proteolytic cleavage or 
unanticipated binding conformations, multivalent affibodies represent a lower risk 
approach to HER3-targeted therapy via engineered multivalent ligands.  
 
In terms of efficacy, both NRG- and affibody-based multivalent ligands promote 
pHER3 inhibition and reduce cancer cell viability, however their mechanisms of 
action appear to be different. Multivalent affibodies had limited impact on HER2 
phosphorylation in the BT474 cell line (Figure 2.7), whereas bivalent NRG efficacy 
is more closely associated with pHER2 inhibition in several cell lines [68], possibly 
via sequestering HER3 into homotypic interactions and preventing HER2/HER3 
heterodimer formation. Alternatively, bivalent NRG, with the ability to bind both 
HER3 and HER4, could be inhibiting pHER2 as a result of blocking HER4-mediated 
signaling. In addition, we observed that bivalent affibodies with predicted linker 
domain lengths of less than 10 nm – theoretically too small to induce a HER3 dimer 
on a one molecule per dimer basis – exhibited similar pHER3 inhibition as constructs 
with longer predicted linker lengths (Figure 2.11). Taken together with the pHER2 
data, pHER3 inhibition by multivalent affibodies may be independent of the ability of 
HER3 to interact with HER2. Another significant result of this study is the 
demonstration that HER3-targeted multivalent affibodies cause rapid and prolonged 
HER3 downregulation, whereas monovalent affibodies have little impact on HER3 
levels (Figure 2.9). This finding that HER3-targeted multivalent affibody efficacy is 
due at least in part to enhanced post-translational receptor downregulation (Figure 
3.2), and is not dependent on pHER2 inhibition, linker domain length, or increased 
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binding affinity to the target molecule provides evidence for potential broad utility of 
multivalent affibodies for targets beyond HER3.  
 
Of course, any discussion of multivalent ligands should include monoclonal 
antibodies (mAbs), which are bivalent in nature. The capability of inducing HER3 
downregulation is variable in HER3 mAbs described in the literature, however a 
tetravalent HER3 antibody has been shown to induce greater HER3 internalization 
compared to its bivalent counterpart [83]. This same study reported diminished 
efficacy of several mAbs against HER3 in the presence of NRG, in contrast to the 
data presented here and highlighting a potential limitation of targeting HER3 
individually with mAbs. Nevertheless, it is notable that several mAbs targeting HER3 
have reached later stage clinical trials [84]. Interestingly, a prior report has shown that 
combinations of two distinct HER3 antibodies did not induce an additive effect [85], 
as has been observed for EGFR [86] and other receptors. The same report indicated 
that acceleration of HER3 degradation is a potentially critical determinant of tumor 
growth inhibition by mAbs, reinforcing the significance of the multivalent affibody-
induced HER3 downregulation observed in the present work. Complete 
understanding of the mechanistic differences between HER3-targeted multivalent 
affibodies (or other multivalent HER3 ligands) and antibodies requires further study, 
however such future studies could also incorporate evaluation of combinations of 




Affibodies, like all molecules, have strengths and weaknesses with regard to their 
therapeutic potential. The structure of affibodies makes them highly stable and 
soluble [58], which is beneficial from a biomanufacturing perspective. The smaller 
size of affibodies relative to mAbs may increase their tumor penetration [87,88], 
although the circulating half-life of affibodies is much shorter than of the typical 
mAb. However, affibodies are easily amenable to formatting for improved 
pharmacokinetics, such as via fusion to an albumin-binding domain [62,89], and such 
constructs are compatible with multivalent presentation. Yet, the enhanced HER3 
downregulation mediated by engineered multivalency reported here is a mechanism 
that can potentially be broadly exploited independently of specific HER3 binding 
domains, linker domain sizes and other molecular idiosyncrasies. Overall, these 
results position multivalent HER3-binding affibodies for further development and 




Chapter 3: Mechanism of Action 
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3.1 Introduction 
Knowledge of the mechanism of multivalent affibody-mediated HER3 
downregulation is important for translation and further rational design. Receptor 
downregulation due to multivalent binding and induced receptor-receptor interactions 
is an established phenomenon. In this Chapter, we also seek to evaluate whether 
multivalent affibody-mediated HER3 downregulation is highly specific to HER3 or 
whether multivalent affibodies specific for other receptors can be employed to induce 
the downregulation of other ErbB receptor family members for therapeutic 
applications. In addition to knowledge regarding the trafficking of HER3, it is crucial 
to understand HER3-specific affibody trafficking, which has broad implications 
toward the rational design and development of HER3 affibodies to deliver toxic 




3.2.1 Receptor downregulation inhibition studies 
Cycloheximide pulse chase: OvCAR8 cells were treated with 10 nM trivalent, 
bivalent or monovalent affibody, or in combination with 178 mM cycloheximide, or 
178 mM cycloheximide alone, lysed at the indicated time points, and probed by 
immunoblot for HER3 and b-Actin.  
 
Proteosomal and Lysosomal Inhibition: OvCAR8 cells were pre-treated with 200 mM 
Leupeptin for 3 hours or no treatment, treated with 10 nM trivalent, bivalent or 
monovalent affibody or in combination with 200 mM Leupeptin, or 200 mM 
Leupeptin alone, lysed at the indicated time points, and probed by immunoblot for 
HER3 and b-Actin. OvCAR8 cells were pre-treated with 5 mM MG-132 for 3 hours 
or no treatment, treated with 10 nM trivalent, bivalent or monovalent affibody alone, 
or in combination with 5 mM MG-132, or 5 mM MG-132 alone, lysed at the 
indicated time points, and probed by immunoblot for HER3 and b-Actin.  
 
3.2.2 HER3 and EGFR downregulation assays  
To examine receptor levels, cells were treated with the indicated concentrations of 
affibody or no treatment (media alone) control, lysed at the indicated time points, and 
the immunoblots probed for HER3 and EGFR as previously described using primary 




3.2.3 Affibody internalization studies 
Internalization probed by fluorescence microscopy: OvCAR8 cells were seeded at 
100,000 cells per well and stored at 37°C or 4°C. 5 uM of Bivalent HER3-GFP in 
37°C or 4°C RPMI 1640 (ATCC) media was added to cells in the corresponding 
temperature conditions and a no treatment group (media only) was added to cells in 
the 37°C condition. All cells containing the factors or no treatment groups were 
incubated for 1 hour at their respective temperatures and then fixed using 2% 
paraformaldehyde (30525-89-4)(Sigma-Aldrich). Cells containing the Bivalent 
HER3-GFP affibodies were probed for fluorescence imaging with primary antibody 
(His-Tag Antibody #2365) obtained from Cell Signaling for 1 hour, followed by 
secondary antibody (Goat anti-Rabbit, Alexa Fluor 350 # A-11046) from 
ThermoFisher Scientific for 1 hour. Media only cells were not probed. Membranes of 
all cells were permeabilized using 0.1% Triton X-100 Detergent Solution 
(28314)(ThermoFisher Scientific). Endosomes of cells were then probed for 
fluorescence imaging with primary antibody (Mouse EEA1 MAB8047-SP) obtained 
from R&D Systems for 1 hour and then secondary antibody (Goat anti-Mouse, Texas 
Red-X # T-6390) from ThermoFisher Scientific for 1 hour. Media only cells were not 
probed. All cells were then imaged using fluorescence microscopy techniques.  
3.3 Results 
3.3.1 Multivalent affibody-mediated HER3 downregulation is at least in part post-
translational 
To verify whether the observed reduction in HER3 levels was post-translational in 
nature, cycloheximide, an inhibitor of protein synthesis, was used in a pulse-chase 
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assay. The half-life of HER3 was not significantly affected by cycloheximide 
treatment over 8 hours and multivalent affibodies induced HER3 downregulation 
after 2, 4, and 8-hour treatments. The downregulation of HER3 by multivalent ligands 
at a much faster rate than the HER3 half-life in OvCAR8 cells suggests that 
multivalent ligands cause reduced HER3 levels at least in part by post-translational 
downregulation (Figures 3.1A, 3.2A). To investigate the possibility of enhanced 
HER3 degradation, OvCAR8 cells were treated with multivalent affibodies in the 
presence or absence of the lysosomal inhibitor leupeptin or the proteasomal inhibitor 
MG-132 and HER3 protein levels were examined by immunoblot. Surprisingly, 
HER3 downregulation by multivalent affibody treatment persisted in the presence of 
leupeptin or MG-132, suggesting that HER3 receptor downregulation may occur via 





Figure 3.1: Multivalent affibody-mediated HER3 downregulation is at least in part post-
translational. A. OvCAR8 cells were treated with 10 nM trivalent, bivalent or monovalent affibody, 
or in combination with 178 mM cycloheximide, or 178 mM cycloheximide alone, lysed at the 
indicated time points, and probed by immunoblot for HER3 and b-Actin. B. OvCAR8 cells were pre-
treated with 200 mM Leupeptin for 3 hours or no treatment, treated with 10 nM trivalent, bivalent or 
monovalent affibody or in combination with 200 mM Leupeptin, or 200 mM Leupeptin alone, lysed at 
the indicated time points, and probed by immunoblot for HER3 and b-Actin. C.  OvCAR8 cells were 
pre-treated with 5 mM MG-132 for 3 hours or no treatment, treated with 10 nM trivalent, bivalent or 
monovalent affibody alone, or in combination with 5 mM MG-132, or 5 mM MG-132 alone, lysed at 
the indicated time points, and probed by immunoblot for HER3 and b-Actin. Results shown are 





Figure 3.2: Immunoblot quantification Figure 3.1: Multivalent affibody-mediated HER3 
downregulation is at least in part post-translational. Quantified HER3 values are displayed for the 
following experiments in OvCAR8 cells: A. cycloheximide pulse chase, and HER3 degradation 
inhibition experiments with B. Leupeptin and C. MG132. Blots were quantified using Odyssey CLx 




3.3.2 Bivalent affibody-mediated HER3 downregulation is a specific phenomenon 
 Given that multivalent HER3 affibodies promote HER3 receptor downregulation, we 
sought to examine to what extent multivalency can be employed as a general tool to 
induce ErbB receptor downregulation. Using a Z-EGFR1907 domain developed by 
Friedman et al. [90], we generated bivalent EGFR-EGFR affibodies as well as 
bispecific, bivalent HER3-EGFR affibody molecules (Figure 3.3A, B) and assessed 
their ability to downregulate HER3 and EGFR receptors (by immunoblot in the 
absence of NRG and EGF) compared to bivalent HER3 affibodies. We observed that 
only positive control HER3 bivalent ligands induced HER3 receptor downregulation, 
while EGFR levels were unaffected by any of the molecules (Figure 3.3C, D, 3.4), 
indicating that HER3 downregulation by multivalent ligands is a specific 
phenomenon. HER3 and EGFR levels were normalized to b-actin levels and the 
results of three independent experiments were quantified in Figure 3.4.  
 
Further, we hypothesized that HER3 downregulation by multivalent ligands is a direct 
result of HER3 sequestration by simultaneous engagement of multiple HER3 
receptors. However, one general mechanism for HER3 inhibition is the blockade of 
heterodimer formation, and the possibility exists that multivalent ligands demonstrate 
improved bioactivity compared to monovalent analogs due to engagement of a single 
HER3 receptor by one HER3 affibody domain, while the un-engaged HER3 binding 
domain acts through HER3-independent steric blockade to inhibit receptor 
heterodimerization and induce HER3 downregulation. To test our hypothesis, we 
assessed the activity of a bivalent HER3-wild type (WT) affibody that incorporated 
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one HER3-binding domain as well as a structurally similar WT affibody domain that 
does not have affinity for HER3 (Figure 3.3C, D, 3.4). HER3 downregulation was 
not observed with HER3-WT affibody, nor with a control monovalent HER3 affibody 
with an attached linker domain, suggesting that HER3 downregulation is not 
idiosyncratic to bivalent molecules but rather requires simultaneous engagement of 






Figure 3.3: HER3 downregulation by multivalent ligands is a specific phenomenon. A. Schematic 
of various affibody constructs: monovalent HER3 (7.6 kDa), HER3 bivalent affibody with 3 or 64 
amino acid linker (14.4 and 19.1 kDa), monovalent EGFR (7.6 kDa), HER3 EGFR bivalent bispecific 
affibody with 3 and 64 aa linker (14.3 and 18.9 kDa), EGFR bivalent affibody with 3 or 64 aa linker 
(14.4 and 18.2 kDa), bivalent bispecific HER3 wild type affibody with 64 aa linker (19.1 kDa), 
monovalent HER3 affibody with 64 aa linker tail (12.5 kDa). B. Purified protein products are 
displayed on a Coomassie stained gel loaded at 10 mg/lane with respective molecular weights listed in 
Figure 3A. C. OvCAR8 cells were treated with 10 nM of the indicated affibody construct, or media 
alone (no treatment), lysed at the indicated time points, and probed by immunoblot for HER3 and b-
actin or D. EGFR and b-actin. All multivalent ligand concentrations refer to the concentration of 




Figure 3.4: Immunoblot quantification of Figure 3.3. Quantified A. HER3 and B. EGFR values are 
displayed for Figure 3. Blots were quantified using Odyssey CLx image system (Licor) Analysis Tool 








3.3.3 Affibody internalization probed with GFP fusion proteins 
To examine if HER3 affibodies are internalized by OvCAR8 cells, we generated 
HER3 affibody C-terminal GFP fusion constructs (Figure 3.5A). Constructs were 
engineered, recombinantly expressed in BL21 (DE3) E. coli, and purified by 
immobilized metal affinity and size exclusion chromatography (Figure 3.5B). 
Bivalent HER3 affibodies retained bioactivity upon fusion with GFP in regard to 
binding to HER3 positive cells (Figure 3.5C,D), and inducing HER3 downregulation 
(Figure 3.5E,F). To determine if bivalent HER3 affibody GFP fusion constructs were 
internalized, OvCAR8 cells were treated with GFP fusion construct for 1 hour at 
either 37C or 4C, and examined by fluorescence microscopy (Figure 3.6). Composite 
images of 37C condition reveal colocalization (yellow) of HER3 affibody GFP 
fusions (green) and endosomes (red), suggesting HER3 affibodies are internalized in 
endosomes. Quantitative analysis revealed approximately 36% of green signal is 
colocalized with endosomes compared with approximately only 5% colocalization at 
4C condition (Figure 3.6). Blue signal indicates affibody binding at the cell surface 
probed by secondary antibody for His Tag present on bivalent GFP fusion proteins 
(Figure 3.6).  In support of our observations from these fluorescence microscopy 
studies, incubation of OvCAR8 cells treated with 10 nM bivalent affibody for 3 hours 
caused complete inhibition of HER3 downregulation (Figure 3.7). Together these 





Figure 3.5: Bivalent HER3 affibodies retain bioactivity upon fusion with GFP. A. Schematic of 
HER3 affibody GFP fusion constructs B. Coomassie gel of purified bivalent and monovalent GFP 
fusion constructs C. OvCAR8 cells were treated with the indicated concentration of bivalent GFP 
affibody construct, or media alone (no treatment), lysed after 5 minutes, and probed by immunoblot for 
GFP and b-actin. D. Immunoblot quantification of C E. OvCAR8 cells were treated with 10 nM of the 
indicated affibody construct, or media alone (no treatment), lysed at the indicated time points, and 
probed by immunoblot for HER3 and b-actin or All multivalent ligand concentrations refer to the 
concentration of individual affibody domains. All blots were cropped. F. Immunoblot quantification of 




Figure 3.6: Bivalent affibody GFP fusion proteins are internalized by OvCAR8 cells. A. 
Composite images of OvCAR8 cells incubated with bivalent affibody GFP at 37C. B. Composite 
images of OvCAR8 cells incubated with bivalent affibody GFP at 4C. C. Quantifications of green/red 
(yellow) colocalization indicating overlay of bivalent GFP with endosomes. Color Guide: Blue (cell 
surface – secondary antibody for His Tag present on bivalent GFP fusion), Green (GFP), Red 
(endosomes).  OvCAR8 cells were seeded at 100,000 cells per well and stored at 37°C or 4°C. 5 uM of 
Bivalent HER3-GFP in 37°C or 4°C RPMI 1640 media was added to cells in the corresponding 
temperature conditions and a no treatment group (media only) was added to cells in the 37°C 
condition. All cells containing the factors or no treatment groups were incubated for 1 hour at their 
respective temperatures and then fixed using 2% paraformaldehyde. Cells containing the Bivalent 
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HER3-GFP affibodies were probed for fluorescence imaging with primary antibody (His-Tag 
Antibody #2365) for 1 hour, followed by secondary antibody (Goat anti-Rabbit, Alexa Fluor 350 # A-
11046) for 1 hour. Media only cells were not probed. Membranes of all cells were permeabilized using 
0.1% Triton X-100 Detergent Solution (28314). Endosomes of cells were then probed by fluorescence 
imaging with primary antibody (Mouse EEA1 MAB8047-SP) for 1 hour and then secondary antibody 




Figure 3.7: Bivalent affibody-mediated HER3 downregulation is inhibited at 4C. A. OvCAR8 
cells were treated with 10 nM of the indicated affibody construct, or media alone (no treatment), lysed 
at the indicated time points, and probed by immunoblot for HER3 and b-actin. All multivalent ligand 
concentrations refer to the concentration of individual affibody domains. Results shown are 
representative of two independent experiments. All blots were cropped. B. Immunoblot quantification 
of A.  
3.4 Discussion 
 
We demonstrate HER3-targeted multivalent affibodies cause rapid and prolonged 
HER3 downregulation, whereas monovalent affibodies have little impact on HER3 
levels (Figure 2.9). This finding that HER3-targeted multivalent affibody efficacy is 
due at least in part to enhanced post-translational receptor downregulation (Figure 
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3.1), and is not dependent on pHER2 inhibition, linker domain length, or increased 
binding affinity to the target molecule provides evidence for potential broad utility of 
multivalent affibodies for targets beyond HER3.  
 
Mechanistically, our data (Figure 3.3C, D 3.4A, B) provide valuable insights into the 
effects of multivalency on enhanced downregulation of HER3 and other receptors. 
The possibility exists that receptor downregulation is a result of enhanced avidity 
effects, endowed through multivalency, and not necessarily a result of simultaneous 
engagement of multiple receptors. In opposition to this possibility, our previous 
results indicate that increasing ligand valency does not increase KD as measured by 
Surface Plasmon Resonance [79]. In the current study, neither monovalent nor 
bivalent EGFR ligands had an effect on total EGFR levels, suggesting that enhanced 
avidity is not a general mechanism enabling ErbB receptor downregulation, and 
indeed HER3 downregulation requires simultaneous engagement of multiple HER3 
receptors.  The HER3 and EGFR affibodies used in this study were observed to be 
inhibitory toward their respective receptors, and here multivalent EGFR ligands were 
not rationally designed to promote EGFR downregulation, but rather to assess 
whether downregulation by multivalent ligands was a receptor specific event.   
 
In addition, future work is necessary to understand the link between HER3 receptor 
downregulation by multivalent ligands and cancer cell survival. For example, HER3 
downregulation may not have a substantial effect on cancer cell death, but instead 
may induce vulnerability due to reduction in Akt-mediated pro-survival signaling, 
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prompting cancer cells to become more susceptible to standard treatments such as 
chemotherapeutics and ErbB-targeted therapies beyond HER3. The majority of 
clinical trials for HER3 antibodies involve their use in combination therapies, for 
example MM-121 combined with docetaxel for non-small cell lung cancer. Future 
investigation of HER3 affibodies in combination with other drugs as well as 
development of HER3-targeting ligands engineered to deliver toxic payloads such as 
chemotherapeutic agents or toxins could represent promising avenues for ovarian 
cancer treatment. 
 
Considering previous reports of receptor downregulation by multivalent ErbB 
therapeutics, to our knowledge, evidence of receptor downregulation by bispecific 
ligands is limited. Neither the HER2-HER3 bivalent bispecific antibody MM-111 
[55], nor the two-in-one antibody HER3-EGFR MEHD7945A [91] were reported to 
induce downregulation or degradation of either target receptor. However, the HER3 
IGF-1R tetravalent bispecific antibody MM-141 was observed to promote 
degradation of both HER3 and IGF-1R, as well as HER2 and insulin receptor [56]. In 
our experiments, monospecific, bivalent EGFR affibodies did not induce EGFR 
downregulation, suggesting that engineered multivalency cannot be applied 
universally as a strategy to downregulate ErbB family target receptors. However, it 
should be noted that previous investigations indicate that multivalency can be used as 
tool to induce EGFR downregulation on a case-by-case basis [13]. Interestingly, MM-
151, a mixture of three monoclonal EGFR antibodies, each binding a unique non-
overlapping epitope on EGFR, was observed to induce EGFR downregulation in 
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multiple cell lines, whereas the combination of MM-151 Fab fragments was not, thus 
demonstrating that multivalency is required for EGFR downregulation in this case 
[13]. In this study, Kearns et al. further demonstrated that each of the three antibody 
components of MM-151 individually promoted EGFR downregulation, with the most 
significant single agent-induced downregulation observed upon treatment with an 
antibody specific for the cetuximab-like epitope on domain III of EGFR extracellular 
domain, yet interestingly, the EGFR monoclonal antibody cetuximab was not 
observed to induce EGFR downregulation [13]. Overall, these data taken altogether 
indicate that multivalency is likely required for EGFR downregulation, however this 
phenomenon appears highly dependent on molecular idiosyncrasies beyond the 
degree of valency, and may include affinity, avidity, binding epitope, degree of 
epitopes targeted, and degree of EGFR crosslinking. 
Chapter 4: HER3 Affibody Efficacy  
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We aim to develop HER3-directed therapeutics specifically for the treatment of 
ovarian cancer, the fifth leading cause of death in woman with an estimated 14,000 
ovarian cancer-related deaths, and an estimated 22,000 new cases of ovarian cancer in 
2017 [92]. The five-year survival rate for ovarian cancer patients is 46.5% [92] and 
HER3 expression is negatively correlated with ovarian cancer patient survival [93]. 
Furthermore, HER3 overexpression has been identified in 16% of patients with 
ovarian cancer [19]. NRG-HER3 autocrine signaling has been identified as a key 
driver of some ovarian cancers, thus HER3 inhibition may be effective in this setting 
[16]. Current treatment options for ovarian cancer are limited and include surgery, 
chemotherapy, hormone therapy, targeted therapy, and radiation therapy [94]. 
Specifically, these targeted therapies include: small molecule PARP inhibitors, and 
VEGF antibodies for angiogenesis inhibition (e.g. Avastin) [94]. HER3 therapies 
would fill a critical clinical need for the treatment of ovarian cancer, and could be 
employed in combination with approved therapies.  
4.2 Methods 
 
4.2.1 Cell proliferation assays 
OvCAR8, Du145, and H1975 cells were seeded at 9,000 cells per well, and BT474 
cells were seeded at 80,000 cells per well in media supplemented with 2% FBS, 1% 
Pen-Strep, and 200 pM NRG in a 24 well plate (VWR 10062-900), treated with the 
indicated concentrations of affibody, PI3K inhibitor NVP-BKM120, combination, or 
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no treatment control (media alone), incubated in 5% CO2 at 37oC for 5 days, and 
analyzed using Alamar Blue (Bio-Rad) following the manufacturer’s protocol.  
4.2.2 Combination treatments 
OvCAR8 cells were seeded at 18,000 cells per well in media supplemented with 2% 
FBS, 1% Pen-Strep, and 200 pM NRG in 24 well plates, treated with the indicated 
concentration of drug (carboplatin, cisplatin, doxorubicin, paclitaxel) or combination 
with 10 nM monovalent or bivalent affibody, and analyzed using Alamar Blue assay 
five days post-treatment.  
4.2.3 Du145 xenograft study  
24 NSG mice were injected with 3 million Du145 cells in media or PBS (no FCS) and 
33% matrigel. Mice were sorted into 3 groups when tumors reached ~ 100 mm3 to 
ensure similar initial mean tumor volume per group. Du145 xenograft bearing mice 
were injected by IP with 80 micrograms bivalent affibody, an equivalent dose of 
monovalent affibody, or PBS alone (8 mice per group) three times weekly every 3 
days for 18 days, and weighed twice weekly. Tumor volume was assessed using 
calipers twice weekly. Mice were sacrificed after 39 days once tumor burden 
exceeded 1500 mm3, and tumors were excised and frozen.   
 
4.2.4 ADR RES Study  
15 NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ NOD SCID gamma (NSG) mice were injected 
with 15x106  luciferase expressing ADR-RES cancer cells by intraperitoneal injection 
(i.p.). Ten days after injection, mice were imaged with IVIS Xenogen In Vivo 
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Imaging System (Perkin Elmer, Bridgeport CT) to monitor disease burden using 
bioluminescence and then the mice were sorted into groups with equivalent mean 
tumor volumes. Mice were injected with 80 micrograms bivalent affibody, an 
equivalent dose of monovalent affibody, or PBS alone (5 mice per group) three times 
weekly via i.p. injection. Tumor burden was monitored weekly by bioluminescent 
imaging using IVIS (Xenogen).  
4.3 Results  
4.3.1 Multivalency increases HER3 affibody-mediated inhibition of cancer cell 
growth  
We examined the effect of multivalent ligands on in vitro cell viability in comparison 
to monovalent affibody treatment. Interestingly, despite the observation of HER3 
signaling inhibition by multivalent affibodies in all cell lines tested, cell viability was 
differentially impacted. In OvCAR8 cells, both bivalent and trivalent HER3 
affibodies (10 nM and 50 nM) significantly reduced viability compared to 
monovalent affibodies (Figure 4.1A). In Du145 cells, multivalent and monovalent 
ligands significantly reduced cell viability compared to untreated controls (Figure 
4.1B). In H1975 cells, multivalent affibody treatment had more limited anti-
proliferative effects compared to monovalent treatment and untreated controls, as 
only the trivalent affibodies caused statistically significant growth inhibition (Figure 
4C). In BT474 cells, neither multivalent nor monovalent treatment reduced 




Figure 4.1: Multivalency increases functional efficacy of HER3 affibodies as single agents and as 
part of combination therapy. A. OvCAR8 B. Du145 C. H1975 D. BT474 cells were exposed to 200 
pM NRG and treated with the indicated concentrations of trivalent, bivalent or monovalent affibodies, 
incubated for 5 days and analyzed using the Alamar Blue assay following the manufacturer’s protocol. 
E. OvCAR8 cells were treated with 50nM of the indicated affibodies in combination with 1mM 
BKM120 (BKM), or with 1mM BKM alone, and incubated and analyzed as above. Results shown are 
mean +/- SD and are representative of three independent experiments; n=10, ***P<0.001, **P<0.01 
*P<0.05 in reference to the equivalent dosage monovalent affibody group, ###P<0.001 in reference to 





4.3.2 Multivalency improves therapeutic efficacy of FDA approved chemotherapy 
drugs 
We explored the utility of bivalent HER3 affibodies in combination therapy with 
various chemotherapeutic drugs: carboplatin, cisplatin, doxorubicin, and paclitaxel. 
Combination with bivalent HER3 affibodies significantly reduced the IC50 values of 
these drugs in OvCAR8 cells compared to monovalent affibody combination 
treatment and single agent chemotherapeutic treatment. Dose curves are shown in 
Figure 4.2. 
Figure 4.2: Multivalency improves therapeutic efficacy of FDA approved chemotherapy drugs. 
OvCAR8 cells were seeded at 18,000 cells per well in media supplemented with 2% FBS, 1% Pen-
Strep, and 200 pM NRG in 24 well plates, treated with the indicated concentration of drug or 
combination with 10 nM monovalent or bivalent affibody A. carboplatin, B. cisplatin, C. doxorubicin, 
D. paclitaxel, and analyzed using Alamar Blue assay five days post-treatment.  
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4.3.3 HER3 affibodies slow tumor progression in vivo in a Du145 xenograft model  
We assessed ligand efficacy in vivo in a Du145 xenograft model (Figure 4.3). 
Bivalent HER3 ABDs significantly slowed tumor progression, albeit modestly, 
compared to PBS control, and this trend persisted even after dosing had been 
terminated. In vivo efficacy was similar between bivalent and monovalent ABD 
fusions in this model.  
 
 
Figure 4.3: HER3 ABD fusions slow tumor progression in vivo in Du145 xenograft model. Mean 
tumor volume over time (Vertical dashed line indicates last treatment day). 24 NSG mice were injected 
with 3 million Du145 cells in media or PBS (no FCS) and 33% matrigel. Mice were sorted into 3 
groups when tumors reached ~ 100 mm3 to ensure similar initial mean tumor volume per group. Du145 
xenograft bearing mice were injected by IP with 80 micrograms bivalent affibody, an equivalent dose 
of monovalent affibody, or PBS alone (8 mice per group) three times weekly every 3 days for 18 days, 
and weighed twice weekly. Tumor volume was assessed using calipers twice weekly. Mice were 
sacrificed after 39 days once tumor burden exceeded 1500 mm3, and tumors were excised and frozen. 
Results shown are mean +/- SE; n=8, *P<0.05 in reference to bivalent versus PBS only treatment at the 





4.3.4 HER3 affibodies reduce tumor progression in vivo in an ovarian cancer 
xenograft model  
We assessed the effect of the affibodies at slowing tumor growth in an orthotopic 
human ovarian cancer model.  The ADR-RES cell line was chosen for this study as it 
is a derivative of the OvCAR8 cell line (from the same patient donor) [95]. NSG mice 
were injected i.p. with 15 million luciferase-expressing ADR-RES cancer cells; 10 
days after injection, mice were i.p. injected with 80 micrograms bivalent affibody, an 
equivalent dose of monovalent affibody, or PBS alone (5 mice per group) three times 
weekly for 28 days. Note, treatment started ten days after cell injection, thus the 
tumors were already engrafted. Bivalent HER3 ABDs significantly reduced tumor 
levels as measured by photon intensity compared to PBS control at days 21 and 28-
post start of treatment. The monovalent HER3 ABDs significantly reduced tumor 




Figure 4.4: HER3-ABD fusions reduce tumor progression in vivo in an ADR-RES xenograft 
model. A. Whole body photon intensity at indicated time points post treatment. B. Raw IVIS images 
Day 21 post treatment. For A and B, 15 NSG mice were injected with 15 million luciferase expressing 
ADR-RES cancer cells by i.p.. 10 days after injection, mice were imaged with IVIS (Xenogen) to 
monitor disease burden and sorted into groups of equivalent mean tumor volumes. Mice were injected 
i.p. with 80 micrograms bivalent affibody, an equivalent dose of monovalent affibody, or PBS alone (5 
mice per group) three times weekly. Tumor burden was monitored weekly by bioluminescent imaging 
using IVIS (Xenogen). Results shown are mean +/- SE; n=5, ***P<0.001 and *P<0.05 indicate 






4.3.3 Discussion  
 
The therapeutic potential of any cancer drug could be further enhanced by selective 
deployment against the most vulnerable cancer types. Our results revealed disparate 
efficacies on the cell lines used in this study, despite the fact that these cells were 
chosen based on biological features that were expected to correlate with HER3-
targeted affibody efficacy. The BT474 cancer cell line is reported to have moderate to 
high levels of HER2 and HER3 [43,78], which together form the most potent 
mitogenic unit of the HER family [20]. The H1975 cell line expresses HER2 and 
HER3 and was previously shown to be susceptible to HER3 biasing by bivalent NRG 
treatment[68]. Additionally, high basal NRG expression has been demonstrated as a 
biomarker for HER3 oncogenic addiction and susceptibility to HER3-targeted 
therapies [43]; both the OvCAR8 and Du145 cell lines are reported to have high basal 
NRG expression [43], and the OvCAR8 cell line has been documented to depend on a 
HER3/NRG autocrine loop [16]. In our studies, multivalent affibodies induced 
significant reductions in cell viability in the OvCAR8, H1975 and Du145 cell lines, 
while BT474 cells were not significantly affected (Figure 4.1). In BT474 cells, this 
lack of efficacy occurred despite enhanced HER3 degradation (Figure 2.9). Thus, our 
data support previous work indicating that HER3 targeted therapies are most 
efficacious as single agents against cancers that exhibit NRG autocrine signaling [43]. 
However, the ability of multivalent affibodies to induce HER3 downregulation 
indicates therapeutic potential for combination therapy approaches, for example, with 





Development of new therapeutic approaches for ovarian cancer is imperative due to 
the generally high rate of recurrence and poor prognosis associated with this disease. 
HER3 is well established as a compelling therapeutic target in numerous cancers, 
including ovarian cancer, yet, conventional small molecule- and monoclonal 
antibody-based approaches have so far failed to yield a widely used therapeutic that 
directly targets HER3. Here, we report the potential of an alternative approach, 
HER3-targeted affibodies. We identify a streamlined and specific molecular format 
for optimal pHER3 inhibition and HER3 downregulation: a bivalent affibody with 
minimal three-glycine linker separating binding domains. We further report 
significant mechanistic evidence supporting HER3 downregulation as a highly 
specific phenomenon prompted by HER3 sequestration by multivalent ligands. Most 
importantly, we show that both monovalent and bivalent HER3 affibody-ABD fusion 
proteins significantly reduce tumor burden in an ADR-RES ovarian cancer model in 
mice, suggesting further exploration of HER3 affibodies as ovarian cancer 
therapeutics.  
 
Taken together with the repertoire of work in the field, the results reported here 
further highlight the translational promise of multivalent ligands for HER3-directed 
cancer therapy. Previous work from the Lofblom group showed that a bivalent 
affibody of molecular format ZHER3-ABD-ZHER3 (3A3), where domains are separated 
by a (S4G)4 linker domain, is capable of simultaneously binding both molecular 
targets HER3 and albumin  [62]. Further, 3A3 showed improved pHER3 inhibition 
compared to monovalent affibody [62], in agreement with our own findings that 
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affibody multivalency improves pHER3 inhibition [79]. 3A3 was also shown to 
significantly reduce pancreatic cancer BxPC-3 xenograft tumor progression in mice 
approximately 26 days post-treatment when dosed at 80 µg treatment 3 times weekly 
[96], and allowed for tumor growth inhibition comparable to monoclonal antibody 
MM-121 when each were dosed at 600 ug 3 times weekly in a similar BxPC-3 in vivo 
model [97]. This report also supports the idea that the efficacy of multivalent HER3 
affibodies can be retained in a variety of formats [97]. Thus, overall, multivalent 
HER3 ligands are versatile and show in vivo therapeutic potential against cancers 
from a variety of source tissues.  
 
Our work here, together with our previous investigation of HER3 multivalent 
affibodies, reveals disparity between in vitro bioactivity versus in vivo efficacy. 
Specifically, in vitro multivalent affibody treatment promotes dramatic reduction in 
HER3 receptor levels and reduced pHER3 levels compared to monovalent affibody 
treatment, whereas in vivo efficacy of multivalent affibodies is comparable to 
monovalent ligands (Figures 4.3 and 4.4). The luciferase expressing ADR-RES 
model used in this work is not a solid tumor model and was therefore not amenable to 
biopsy for the assessment of HER3 levels post-treatment. Thus, it remains to be 
definitively shown whether multivalent affibodies induce similar HER3 
downregulation as observed in vitro. Regardless, further investigation is likely 
required in order to realize the full potential of multivalent ligands compared to 
monovalent ligands in vivo through exploration of alternative dosing levels, treatment 
regimens, and cancer models.  
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Beyond our focus here on multivalent HER3 affibodies for ovarian cancer therapy 
and induced receptor downregulation, it is important to highlight that affibodies and 
alternative protein scaffolds in general represent an emerging field of significant 
industrial and clinical interest for myriad therapeutic applications. Numerous 
alternative scaffold-based therapies are in on-going clinical trials for treatment of a 
variety of pathologic conditions, including the affibody therapeutic AB-035, an IL-
17A-specific affibody for the treatment of psoriasis, and AB7-25, a HER2 specific 
affibody for cancer PET imaging [98–100]. Affibodies possess inherent strengths and 
weaknesses compared to the standard IgG antibody therapeutics. Affibodies have 
superior tissue penetration (due to their small size), enhanced stability, ease of 
manufacturing and expression in bacterial systems, and low immunogenicity [98–
100]. The limitations of affibody therapeutics, namely their short half-life and lack of 
immune effector function, can easily be overcome through molecular engineering 
approaches tailored to the specific application of interest. For instance, affibodies 
incorporating albumin-binding domain fusion partners are reported to display 
extended half-life of up to 12 days [98]. HER3 affibodies proved highly amenable to 
molecular engineering approaches, as modulation of linker length, valency, and ABD 
fusion placement allowed for robust retention of HER3 affibody bioactivity. Thus, the 
versatility and modular potential of affibody molecules are advantageous toward the 





Regarding the treatment of ovarian cancer, this work provides proof of principle for 
multivalent ligands as a promising strategy to limit in vivo ovarian cancer 
progression. OvCAR8 and ADR-RES cell lines are representative models of high-
grade serous ovarian cancer (HGSOC), a highly aggressive and common ovarian 
cancer subtype. The results herein encourage a more extensive evaluation of 
multivalent HER3 ligands against a broad panel of HGSOC cell models, which may 
help identify biomarkers of susceptibility to HER3-targeted therapies, and enable the 
strategic deployment of such therapeutics against ovarian cancer in a more 
personalized medicine approach.   
 
Chapter 5: Delivering Toxic Payloads via Next Generation 
HER3 Affibody Anti-Cancer Therapeutics  
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5.1 Introduction 
Recombinant immunotoxins have emerged as promising therapeutic modalities for 
the treatment of cancer. This technology combines the natural potency of protein 
toxins to induce apoptosis and kill cells with the targeting ability of antibodies (and 
other high affinity binding domains) towards the ultimate goal of selective delivery of 
toxic payload to cancer cells without deleterious off-target effects on healthy cells and 




Pseudomonas exotoxin A (PE) is a 613 amino acid protein with molecular weight of 
66.7 kDa. Structurally, it contains three major domains: a cell-binding domain 
(Domain 1 – Residues 1-252), a translocation domain (Domain 2 – Residues 253-
364), and a protein synthesis arrest and programmed cell death induction domain 
(Domain 3 – Residues 396-613) [103]. Initial efforts in developing immunotoxins 
involved the incorporation of full-length toxins, which caused severe toxicity in in 
vivo pre-clinical models [102,104]. This limitation led to the engineering of PE38, a 
38 kDa truncated PE format with reduced off target toxicity. Specifically, PE38 was 
engineered with a deletion of the domain 1 cell-binding moiety; PE38 contains amino 
acids 251-364 followed by amino acids 381-613 of PE based on Protein Data Bank 
structure 1IKQ [105]. To generate recombinant immunotoxin, an antibody fragment 
(or other high affinity binding domain) can traditionally be engineered as an N-
terminal fusion protein to direct toxin to the cells overexpressing a specific target of 
interest.  
 
For immunotoxin to induce cell death, an orchestrated succession of molecular 
therapeutic trafficking events must occur. First, the immunotoxin must enter 
endocytic compartments within the target cell [102]. Notably, the truncated PE38 
lacks a cellular binding domain (domain I), and it is therefore requisite that the 
antibody or high affinity-binding domain endows the immunotoxin with the function 
of cellular uptake into endocytic compartments [102]. Once, the immunotoxin enters 
the endocytic compartment, PE38 is cleaved into two fragments [102]. The C-
terminal domain, composed of domain III and a portion of domain II, translocates 
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into the ER, and then to the cytosol [102]. There, the cell death induction domain 
(Domain III) exerts its adenosine diphosphate (ADP)-ribosylation enzymatic activity 
by modifying elongation factor 2 with ADP ribose, ultimately causing protein 
synthesis arrest and cell death [102].  
 
The first immunotoxin to be granted FDA-approval was denileukin diftitox (ONTAK) 
(approved in 1999) [104,106]. ONTAK is a diphtheria toxin IL-2 fusion protein, 
which has been employed clinically for the treatment of cutaneous T cell lymphoma 
(CTCL), Non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL) 
[104,106]. Diphtheria toxin induces cell death by near analogous mechanism to that 
of PE38. There are several immunotoxins in clinical trial incorporating diphtheria 
toxin, PE38, and other toxin moieties [106]. Immunotoxins incorporating PE38 in 
clinical trial include: (1) BL22, which contains a CD22 mAb, for the treatment of 
hairy cell leukemia (HCL), and  (2) LMB-2, which contains the variable region of an 
anti-CD25 mAb, for the treatment of T cell malignancies and HCL [106].  While 
immunotoxins have most frequently been investigated as therapies for hematologic 
cancers, there are several on-going clinical trials pursuing immunotoxins for the 
treatment of solid tumors and metastatic cancers e.g. LBM-100, a mesothelin specific 
antibody-PE38 toxin fusion, for the treatment of mesothelioma [106]. Solid tumors 
present considerable added challenge compared to hematologic cancers toward 
effective treatment with immunotoxins [106]. Solid tumors are naturally less 
accessible to targeted therapy.  Further, patients with solid tumors are generally less 
immunocompromised (compared with patient’s with hematological malignancies) 
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and are therefore more likely to develop acquired immunotoxin resistance – by 
mechanism of neutralizing antibody production [106].  
 
5.2 Methods 
5.2.1 Preparation of Recombinant Immunotoxin 
Cloning of HER3 bivalent affibody PE38 Fusion Protein: DNA gene block (IDT) 
encoding HER3 bivalent affibody was ligated into pRK79 protein expression vector 
immediately upstream of DNA encoding truncated Pseudomonas exotoxin (PE38) 






and expression vector pRK79 were each digested with HindIII and Nde1 restriction 
enzymes following manufacturer’s protocol (NEB), and ligated using Gibson 
assembly reagent (NEB). Positive clones were examined by DNA digest, and 
sequences were confirmed by Sanger Sequencing at NCI Core Facility.  
 
Transformation: BL21 (DE3) E. Coli Cells were transformed following 
manufacturer’s protocol with 200 ng plasmid DNA. Transformed cells were plated on 
five LB/Chloramphenicol agar plates (200ul per plate) and incubated overnight at 




Fermentation: Super Broth was prepared (1 Liter of Terrific Broth was supplemented 
with 8.9 mL of 45% glucose solution, 1.68 mL of 1M MgSO4, and chloramphenicol). 
All colonies from five plates were dislodged with 5 mL Super Broth, and used to 
inoculate 2-500mL cultures in baffled, 1L Erlenmeyer flasks in an environment of 
37C, shaken at 250 RPM. Cultures were monitored for approximately two hours until 
OD600nm was between 2.0-2.5, and then induced with a final concentration of 1mM 
IPTG. Culture continued to shake at 37C for an additional 2 hours after induction. 
Bacteria were harvested by centrifugation at 3500 rpm for 20 minutes, supernatant 
was discarded, and cell pellet was stored at -80C. Samples of pre- and post- induction 
of both soluble and insoluble fractions were analyzed via SDS-PAGE gel stained with 
coomassie.  
 
Inclusion body preparation: Pellet was resuspended in 160mL of TES (50 mM Tris-
HCl, pH 8.0, 20 mM EDTA, 100 mM NaCl), and treated with 6.5 mL of lysozyme (5 
mg/ml in water). Solution was mixed using Tissuemizer probe and incubated at room 
temperature for 30 minutes, shaken manually every 10 minutes. 20 mL of 25% Triton 
X100 solution (in water) was added to the solution, and it was mixed using the 
Tissuemizer to sheer DNA. The solution was incubated at room temperature for 30 
minutes, shaken by hand every 10 minutes. The solution was centrifuged at 12,000 
rpm at 4C for 20 minutes, and the supernatant was discarded. The process of 
suspension in TES, incubation with 25% Triton X100, mixing, centrifugation, and 
discarding of supernatant was repeated two more times, and then this process was 
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repeated three times washing without Triton X100. Finally, the inclusion body was 
pelleted by centrifugation and stored at -80C.  
 
Solubilization and denaturation: The inclusion body was resuspended in 5 mL GTE 
buffer (6 M guanidine HCl, 100 mM Tris-HCl, pH 8.0, 2 mM EDTA), incubated at 
room temperature for two hours, and then centrifuged at 12,000 rpm. The solubilized 
protein in the supernatant was collected, and quantified for protein content by Pierce 
Coomassie Plus reagent. Then, protein solution was diluted to 10 mg/ml in GTE 
buffer supplemented with 10 mg/ml dithioerythritol to reduce disulfide bonds on the 
toxin domain, and incubated at room temperature for 5 hours, protected from light.  
 
Refolding: Denatured protein was added dropwise to 1 L chilled refolding buffer (100 
mM Tris-HCl, 1 mM EDTA, 0.5 M arginine, pH 9.5, 551 mg/L oxidized glutathione 
– added just before use) and incubated for 24 hours. Then, folded protein solution was 
dialyzed against 50L dialysis buffer (20 mM Tris-HCl, pH 7.4, chilled to 4°C, 100 
mM urea – added just before use. 
 
Chromatography: Q-Sepharose ion exchange column was equilibrated with 10 
column volumes chromatography buffer A (20 mM Tris-HCl, pH 7.4, 1 mM EDTA), 
10 column volumes chromatography buffer B (1 M NaCl in Chromatography buffer 
A), and then 10 column volumes chromatography buffer B.  Q-Sepharose column was 
loaded with protein solution. Q-Sepharose column was then connected to AKTA 
chromatography system, and protein was eluted by 50% buffer B gradient over 30 
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minutes. Fractions were assessed for protein content and purity by coomassie gel. 
Selected fractions were consolidated and loaded onto an 8 mL Mono-Q ion exchange 
column (equilibrated in Buffer A as described for Q-Sepharose column). Mono-
column was connected to AKTA chromatography system, and eluted by 50% buffer 
B gradient over 60 minutes. Fractions were assessed for protein content and purity by 
coomassie gel, and selected fractions were further purified, and buffer exchanged to 
Phosphate-buffered saline (20 mM KH2PO4, 50 mM Na2HPO4, 0.15 M NaCl, pH 
7.4) using Progel TSK G3000SW size exclusion column.  
 
The methods outlined in Section 5.2.1 are adapted from Pastan et al. Recombinant 
Immunotoxins in the Treatment of Cancer. 2004 [103].  
 
5.2.2 Assessment of recombinant immunotoxin in vitro bioactivity 
OvCAR8 cells were seeded at 18,000 cells per well in media supplemented with 2% 
FBS, 1% Pen-Strep, and 200 pM NRG in a 24 well plate (VWR 10062-900), treated 
with the indicated concentrations of bivalent HER3 PE38 immunotoxin, HB21 
immunotoxin (positive control), or no treatment negative control (media alone), 
incubated in 5% CO2 at 37oC for 5 days, and analyzed using Alamar Blue (Bio-Rad) 




5.3 Results and Discussion  
5.3.1 Preparation of bivalent HER3-PE38 toxin fusion  
DNA encoding Bivalent HER3 affibody was cloned upstream of PE38 toxin in 
plasmid pRK79. The protein was expressed in BL21 (DE3) E. coli in 2-500mL 
cultures. Bivalent HER3 affibody-PE38 toxin fusion was identified in the insoluble 
protein fraction, only after induction of protein expression with IPTG as indicated by 
a distinct band of expected size (theoretical molecular weight of 51.453 kDa) by 
SDS-PAGE gel stained with coomassie (Figure 5.1). This approximately 50 kDa 
band was visible only in the insoluble fraction post-IPTG induction. To purify the 
recombinant immunotoxin, the insoluble protein fraction was isolated, cells were 
lysed, and the inclusion body was washed extensively to remove contaminates e.g. 
DNA. Coomassie stained SDS-PAGE gel of washed inclusion body revealed a 
distinct band of expected size (Figure 5.2). The isolated inclusion body was 
solubilized by suspension in guanidine rich buffer and homogenization using 
Tissuemizer probe. The solubilized protein yield was approximately 70 milligrams 
(per 2-500mL cultures) as determined by Pierce Coomassie Plus reagent following 
manufacturer’s protocol and in reference to BSA standard curve. To isolate bioactive, 
recombinant immunotoxin, the solubilized protein was denatured, refolded, dialyzed, 
and purified via three stages of chromatography. First, Q-Sepharose ion exchange 
chromatography was employed as a cost-effective initial step to remove crude high 
molecular weight contaminants and aggregates. Q-Sepharose gradient 
chromatography introducing high salt buffer resulted in protein elution as a single 
peak for absorbance at 280nm, and the corresponding fractions were examined for 
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purity and protein content by Coomassie stained SDS-PAGE gel. The results revealed 
that the majority of fractions contained thick bands at expected molecular weight 
approximately 50 kDa (indicative of the recombinant immunotoxin), but also several 
higher molecular bands (indicative of aggregates and impurities) (Figure 5.3). 
Fractions illustrated with ‘X’ were discarded based on low concentration and high 
impurity relative to the level of 50 kDa band (Figure 5.3). Total approximate protein 
content determined by Nanodrop (E=12.43 for our recombinant immunotoxin) was 70 
mg, indicating limited loss of protein product during Q-Sepharose chromatography.  
To more stringently purify the immunotoxin, Mono-Q ion exchange chromatography 
was employed again introducing a gradient of high salt to elute the protein, resulting 
in the elution of two distinct peaks. Coomassie stained SDS-PAGE gel of fractions 
B9-B5 (peak 1) and C1-C6 (peak 2) collected after Mono-Q chromatography indicate 
that Mono-Q separated with high purity bivalent HER3 affibody-PE38 toxin fusion 
protein (peak 1) from higher molecular weight aggregates and impurities (peak 2) 
(Figure 5.4). Total approximate protein content determined by Nanodrop was 
approximately 35 mg, indicating that approximately half of solubilized inclusion 
body proteins were recombinant immunotoxin monomer, assuming limited loss of 
total protein during Mono-Q chromatography stage. As a final polishing and buffer 
exchange step to PBS (for the peak 1 Mono-Q fractions), size exclusion 
chromatography was employed, and resulted in the elution of a single peak at 
absorbance 280nm. Coomassie stained SDS-PAGE gel and Nanodrop respectively 
confirmed high purity fractions (Figure 5.5) and total protein content approximately 
30 mgs. The purified recombinant immunotoxin fractions were consolidated and 
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examined on a Coomassie stained SDS-PAGE gel at 2.5 ug/lane in reference to 
control well loaded with 2.5 ug BSA (Figure 5.6), reinforcing the result of a high 
purity product of expected molecular weight and band intensity comparable to that of 
BSA control (to confirm concentration).  
5.3.2 Assessment of recombinant immunotoxin in vitro bioactivity 
To assess in vitro bioactivity of bivalent HER3-PE38 toxin fusion protein, OvCAR8 
cells were treated with indicated concentrations of bivalent HER3 PE38 
immunotoxin, HB21 immunotoxin (positive control), or no treatment negative control 
(media alone), incubated for 5 days and analyzed using the Alamar Blue assay. The 
results indicate that bivalent HER3 PE38 immunotoxins exhibit potent bioactivity, 
reducing cell survival to approximately 10% of no treatment negative control at 
dosing around 200 nM, and 35% of negative control value at 20 nM treatment 
(Figure 5.7). Bivalent HER3 Affibody PE38 did, however, exhibit significantly lower 
bioactivity than positive control HB21, a PE40 immunotoxin directed to human 
transferrin receptor (expressed on OvCAR8 and many cancer cell types) by 
monoclonal antibody variable region fusion. HB21 showed substantial cell killing 
(around 10% of negative control no treatment cells) even at subnanomolar 
concentrations (Figure 5.7). Overall, these results – confirming potent cell death 
induction by bivalent HER3 affibody PE38 immunotoxin – provide crucial proof of 
concept for effective intracellular delivery of toxic payload to cancer cells. It is well 
established that PE38 alone has limited toxicity because it is not readily internalized 
by cells [101]. Thus, HER3 affibodies successfully traffic PE38 inside OvCAR8 cells. 
These results encourage further evaluation of bivalent HER3 PE38 affibodies for 
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HER3-positive cancer treatment, and crucially indicate promise for HER3 affibodies 
to be employed for intracellular delivery of various therapeutic cargo (e.g. 
chemotherapeutic small molecule drugs) in HER3 affibody-drug conjugate 





Figure 5.1: Bivalent HER3 affibody PE38 toxin fusion is identified as insoluble protein. 
Coomassie stained SDS-PAGE gel of soluble and insoluble protein fractions before and after induction 
of protein expression with IPTG; samples were loaded at 5 ul (first four lanes to the right of the ladder) 
and 10 ul (last four lanes on the right) total volumes. Bivalent HER3 affibody PE38 toxin fusion 
protein has theoretical molecular weight of 51.453 kDa. A distinct band of expected size is visible in 
the insoluble protein fraction only after induction of protein expression. Briefly, 2-500mL cultures 
were inoculated in an environment of 37C, shaken at 250 RPM. Cultures were monitored for 
approximately two hours until OD600nm was between 2.0-2.5, and then induced with a final 






Figure 5.2: Bivalent HER3 affibody-PE38 toxin fusion protein is identified in washed inclusion 
body. Coomassie stained SDS-PAGE gel of soluble and insoluble protein fractions before and after 
induction of protein expression with IPTG, and washed inclusion body. Bivalent HER3 affibody-PE38 
toxin fusion protein has theoretical molecular weight of 51.453 kDa. A distinct band of expected size is 
visible in the washed inclusion body. Briefly, pelleted insoluble protein fraction was resuspended in 
160mL of TES buffer, and treated with 6.5 mL of lysozyme (5 mg/ml in water). Solution was mixed 
using Tissuemizer probe and incubated at room temperature for 30 minutes, shaken manually every 10 
minutes. 20 mL of 25% Triton X100 solution (in water) was added to the solution, and it was mixed 
using the Tissuemizer to sheer DNA. The solution was incubated at room temperature for 30 minutes, 
shaken by hand every 10 minutes. The solution was centrifuged at 12,000 rpm at 4C for 20 minutes, 
and the supernatant was discarded. The process of suspension in TES, incubation with 25% Triton 
X100, mixing, centrifugation, and discarding of supernatant was repeated two more times, and then 






Figure 5.3: Purification of refolded protein (from inclusion body fraction) via Q-Sepharose ion 
exchange column. Coomassie stained SDS-PAGE gel of fractions A5-B12 corresponding with A280 
chromatography peak reveals that fractions contain thick band of expected molecular weight 
approximately 50 kDa, but also several higher molecular bands indicative of aggregates/impurities. 
Fractions illustrated with ‘X’ were discarded based on low concentration and high impurity relative to 
50 kDa band. Briefly, Q-Sepharose column was loaded with refolded inclusion body protein solution. 
Column was then connected to AKTA chromatography system, and protein was eluted by 50% buffer 






Figure 5.4: Purification of selected, consolidated fractions by Mono-Q ion exchange 
chromatography. Coomassie stained SDS-PAGE gel of fractions B9-B5 (peak 1) and C1-C6 (peak 2) 
collected after Mono-Q chromatography.  The results indicate that Mono-Q successfully separates 
bivalent HER3 affibody PE38 toxin fusion protein (expected molecular weight approximately 50 kDa) 
from higher molecular weight aggregates and impurities. Briefly, Mono-Q column was loaded with 
selected fractions, column was connected to AKTA chromatography system, and protein was eluted by 






Figure 5.5: Size exclusion purification and buffer exchange of bivalent HER3 affibody-PE38 
toxin fusion. Coomassie stained SDS-PAGE gel of fractions collected after size exclusion 
chromatography corresponding with A280 single peak. Briefly, selected fractions post Mono-Q 
chromatography (B7 and B6) were buffer exchanged to Phosphate-buffered saline (20 mM KH2PO4, 
50 mM Na2HPO4, 0.15 M NaCl, pH 7.4) using Progel TSK G3000SW size exclusion column 






Figure 5.6: Bivalent HER3-PE38 toxin fusion protein – Purified product. Coomassie stained SDS-
PAGE gel of final, consolidated protein product loaded at 2.5 ug/lane in both non-denaturing and 
denaturing (BME treatment and 5 minute incubation at 95C) compared against reference standard of 





Figure 5.7: Assessment of in vitro bioactivity of bivalent HER3-PE38 toxin fusion protein.  
OvCAR8 cells were exposed to 200 pM NRG and treated with the indicated concentrations of treated 
with the indicated concentrations of bivalent HER3 PE38 immunotoxin, HB21 immunotoxin (positive 
control), or no treatment negative control (media alone), incubated for 5 days and analyzed using the 
Alamar Blue assay following the manufacturer’s protocol. Results shown are mean +/- SE, n=3. 
 
Chapter 6: Future Directions  
The results herein demonstrate HER3 multivalent ligands as promising molecular 
therapeutics for improved cancer treatment. Yet, further investigation of HER3 
affibodies is needed in order to realize the full potential of these molecules. HER3 
affibodies should be engineered for optimized efficacy and employed against the 
most vulnerable cancers. We show that bivalent affibodies with small glycine linker 
separating affibody domains allow for optimized HER3 downregulation, pHER3 
inhibition. HER3 affibodies show modest cancer cell proliferation inhibition and can 
foreseeable be applied in combination, conjugation, and toxin fusion protein based 
approaches to enhance overall therapeutic efficacy. We demonstrate that bivalent 




A key next step is to more rigorously investigate the potential of our toxin delivery 
approach. First, we plan to confirm that multivalent HER3 affibody PE38 fusions 
retain the ability to downregulate HER3 receptor (assessed by immunoblot).  We next 
plan to engineer monovalent PE38 toxin fusions to examine any differential effects. 
Notably, multivalent but not monovalent HER3 affibodies induce HER3 
downregulation. If multivalent HER3 ligands are endocytosed as a result of HER3 
receptor internalization due to multivalent binding events, we would expect to see 
differential in vitro bioactivity comparing monovalent and bivalent PE38 fusion 
ligands. Albumin binding domains have been employed by our research group and 
others to improve HER3 affibody half-life and in vivo efficacy. We will generate 
HER3 affibody – albumin binding domain – PE38 fusion proteins and evaluate these 
molecules in vivo in ovarian cancer xenograft models. One potential pitfall is that 
HER3 PE38 toxin fusions may exhibit low tolerability due to toxicity when evaluated 
in vivo. The pilot study of HER3 affibody PE38 immunotoxin (Chapter 5) has 
provided valuable proof of concept for effective intracellular delivery of toxic 
payload to cancer cells. If dose-limiting toxicity thwarts the promise of our 
immunotoxin approach, we will pursue HER3 affibody-drug conjugate approaches 
for the targeted delivery of chemotherapeutic agents to cancer cells.  
 
Beyond engineering of affibodies in fusion and conjugation-based approaches to 
improve overall efficacy, another key objective of our on-going research is to 
conclusively elucidate the mechanism of HER3 downregulation by multivalent 
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ligands. Understanding this mechanism will provide fundamental knowledge on 
HER3 receptor biology; this knowledge can ultimately be applied toward the 
improved rational design of cancer therapies against HER3. Thus far, we know that 
HER3 downregulation by multivalent ligands is at least in part post-translational in 
nature, however classic inhibitors of degradation pathways and combinations thereof 
have shown limited ability to inhibit the observed downregulation phenomenon. We 
are able to inhibit HER3 downregulation by multivalent ligands by incubation at 4C 
indicating an active mechanism of downregulation. However, this result does not 
provide conclusive evidence toward differentiating between either (i) receptor 
shedding or (ii) receptor endocytosis, since incubation at 4C could foreseeable inhibit 
either process. Further, we present evidence that multivalent HER3 affibodies are 
internalized via endocytosis, suggesting that HER3 receptors are also internalized by 
this mechanism. A key next step is to examine HER3 downregulation by multivalent 
ligands in the context of comparison with HER3 downregulation by native ligand 
neuregulin, a process that is well-understood [107,108]. For instance, HER3 
downregulation induced by NRG results in upregulation of Nrdp1, a cytoplasmic 
HER3 interaction partner [107]. By carefully examining HER3 downregulation in 
relationship to NRG-mediated HER3 downregulation in MCF-7 cells as a control 
system, we hope to gain new insights into HER3 downregulation by multivalent 
ligands, and potentially uncover a novel mechanism of action for HER3 




Beyond gaining fundamental understanding in HER3 receptor biology as a future aim 
of our research, we will continue to identify the most vulnerable cell types to HER3 
multivalent affibodies. Our in vivo efficacy data support that HER3 affibodies are 
promising toward the treatment of ovarian cancer. We hypothesize that HER3 
expression and NRG expression will be key indicators of susceptibility to HER3 
affibodies. We are conducting on-going research to examine the utility of HER3 
multivalent ligands in ovarian cancer cell models that best recapitulate ovarian cancer 
patient tumors. Specifically, we are screening HGSOC and clear cell ovarian cancers 
for HER3 and NRG and evaluating this data in relationship in vitro cancer cell 
survival data in response to HER3 affibody treatment.  
  
The overarching goal of our continued research is to position HER3 therapeutics for 




Appendix A: Affibody Construct Protein and DNA Sequences 
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